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Introduction
This Venice Chart International Consensus Document on
atrial fibrillation (AF) ablation represents an update of the
initial document published in the Journal of Cardiovascular
Electrophysiology in 2007.1 Since then, many technological
developments and progress have been made and AF ablation
has become a well-established, widespread treatment for pa-
tients with AF.
Anatomy of Structures Relevant to Atrial Fibrillation
Ablation
Over the last decade, ablation of AF has focused on the
left atrium (LA) and this has stimulated further investigation
on gross and microscopic anatomy of the LA and of the
neighboring structures. Knowledge of their architecture and
mutual relationships is necessary to access, map, and ablate
the LA in a safe and successful way.
The anatomy and position of the fossa ovalis are major
determinants for the electrophysiologists’ ability to safely
access the LA through transseptal catheterization. The di-
mensions of the fossa ovalis (average vertical diameter of
19 mm, average horizontal diameter of 10 mm, thickness of
1–3 mm)2 allow a safe double transseptal puncture. Table 1
reports the congenital or acquired disorders of the chest and
cardiovascular structures possibly affecting the location of
the fossa ovalis and, therefore, resulting in a more difficult
transseptal access. Similarly, multiple previous transseptal
catheterizations causing fibrosis of the fossa ovalis are the
major variables associated with difficult puncture and pene-
tration of the transseptal needle.3 Transseptal catheterization
in the presence of a device occluding the fossa ovalis is pos-
sible, because its position is more cranial as compared to
the fossa ovalis position.4 However, a careful approach and
additional imaging are mandatory.
Three-dimensional (3D) imaging of the LA and pul-
monary veins (PVs) shows a wide range of variants of their
anatomy.5 Specifically, the typical PV branching pattern with
4 distinct PV ostia (Fig. 1C) is present in approximately 20–
60%, while a very frequent anatomical variant is the presence
of a short or long common left trunk, observed in up to 75–
80% of cases. The presence of supernumerary PVs, mainly
right middle PV or right upper PV, is reported in 14–25%
of cases. The criss-cross of myocardial fibers and the in-
creased thickness of the muscular sleeves at the interpulmu-
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TABLE 1
Congenital or Acquired Disorders of the Chest and Cardiovascular





–Persistence of left superior vena cava
–Pericardial agenesia
–Dextrocardia
–Aortic or mitral valve disease
–Marked dilatation of the ascending aorta
–Marked left ventricular hypertrophy
–Previous cardiac surgery
Figure 1. (A) The left atrium viewed from the left side and dissected to
show the myocardial strands extending over the left superior and inferior
pulmonary veins (LSPV, LIPV). The left atrial appendage (LAA) is finger-
like in shape. (B) This histologic section taken through the left pulmonary
veins shows myocardial strands crossing between the veins (blue arrows).
Masson’s trichrome stain. (C) This histologic section shows the 4 pulmonary
veins with myocardial extensions (stained brown) over the outer surface of
the veins. The ovals indicate the veno-atrial junctions. Note the non-uniform
thickness of the left atrial walls. The superior caval vein (SVC) is seen in
cross section with its myocardial sleeve (green arrows). Elastic van Geison
stain. RIPV, RSPV = right inferior, right superior pulmonary veins.
nary isthmus between the orifices of the ipsilateral PVs with
the possibility of epicardially located intervenous muscular
connections (Fig. 1B) may represent the anatomical basis
for the complexity to achieve a permanent PV isolation by
ablation techniques.6 Another critical structure for ablation
procedure is the ridge or carine between LA appendage and
left PVs (Fig. 1A). The ridge may be flat, round, or pointed
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TABLE 2
Key Points Regarding the Anatomy of Structures Relevant to AF Ablation
–Some congenital and acquired disorders of the chest and cardiovascular
structures, multiple transseptal catheterizations, and the presence of a
device occluding the fossa ovalis are all potential causes of more difficult
transseptal access.
–Owing to the wide range of anatomical variants, 3D reconstruction of LA
and PVs by means of imaging techniques is considered essential to
perform AF ablation in a safe and successful way.
–Understanding the anatomical relationship between the LA and both the
esophagus and the phrenic nerves is crucial to avoid collateral damage of
these structures during AF ablation.
in profile and is <5 mm wide in 75% of hearts suggesting
that achieving catheter stability for adequate contact can be
challenging most cases.
Understanding the anatomic relationship between the
LA/PV orifices and the left atrial ganglionated plexi (GP)
explains how ablation in the LA not only results in PV elec-
trical disconnection but it may cause also modification of
the autonomic tone influence with an impact on the elec-
trical activity.7 Transmural lesions8 in the medial region of
the LA, septum and/or proximal coronary sinus (CS) may
disrupt interatrial conduction pathways alternative to con-
duction over the Bachmann’s bundle and, consequently, alter
the postablation atrial propagation pattern.
The very strict anatomical relationship between the LA
and both the esophagus and the phrenic nerves9,10 is the
major cause of concern of collateral damage to these 2 struc-
tures during AF ablation, resulting rarely in severe patient
injury. Assessment of the individual anatomy, reduced power
and continuous monitoring of the effect of ablation on these
structures are all possible means to avoid their permanent or
severe damage.
The key points regarding the anatomy of structures rele-
vant to AF ablation are reported in Table 2.
Pathophysiology of Atrial Fibrillation
The pathogenesis of AF is often multifaceted and the
arrhythmia may develop in different disease conditions as
well as in the normal heart. It is well recognized that in-
creased atrial mass, decreased conduction velocity, and de-
creased atrial refractoriness with increased dispersion are all
pro-fibrillatory factors. Irrespective of the underlying mech-
anism, the onset and maintenance of AF requires an event
(trigger) that initiates the arrhythmia and the presence of
a predisposing substrate that perpetuates it. Additional fac-
tors (e.g., inflammation or autonomic tone) may also cooper-
ate as “modulators” in facilitating initiation or continuation
of AF.
Diseases Associated with AF and the Role of Fibrosis
Although approximately 10% of AF patients have no ev-
ident cardiac disorder (so-called “lone” AF), the arrhythmia
usually occurs in patients with structural heart disease. Hy-
pertension, coronary heart disease, valvular heart disease, di-
lated cardiomyopathy, and heart failure are the most frequent
pathological conditions associated with AF. Atrial enlarge-
ment is often present, although it is difficult to establish if it
represents the cause or the consequence of AF. Atrial fibrosis
and loss of myocardial tissue may be either a substrate for
AF (due to coexisting heart disease) or a result of fibrillating
atria and part of the so-called structural remodeling.11
Genetic Factors and Ion Channel Diseases
A number of studies provide irrefutable evidence for a
genetic component in the case of lone AF.12 Genetic linkage
analyses have revealed AF chromosome loci for genetic de-
fects in various potassium channels and the gap junctional
protein Connexin40.13 Relatively rare forms of familial AF
have also been associated with inherited channelopathies
such as Brugada, long QT and short QT syndromes, as well
as with cardiomyopathies.13,14
Electrophysiological Mechanisms
Increased automaticity and single and multiple circuit
reentry can cause AF. These mechanisms are not mutually
exclusive; it is likely that areas of focal firing and areas of
reentry are present simultaneously in varying degrees in the
majority of patients.
AF Triggers and Sources
The PVs are an important source of ectopic beats; they are
capable of initiating frequent paroxysms of AF, which can
be eliminated by treatment with radiofrequency ablation.15
Other anatomical structures that may also provide ectopic
beats triggering AF are the superior vena cava, the vein of
Marshall, the musculature of CS, the posterior wall of the
LA, and LA appendage.16
The Third Dimension
The 3D anatomical structure of the atrial muscle is likely
to be a crucial factor in determining the ultimate fibrilla-
tory behavior. Indeed, high frequency stimulation of the PVs
originates wavebreaks in areas of abrupt fiber orientation and
wall thickness changes in the posterior wall of the LA.17
Role of the Autonomic Tone
The autonomic tone is thought to play an important role
in the pathogenesis of AF. Vagal stimulation shortens refrac-
tory period, and sympathetic stimulation increases calcium
loading and automaticity. Combined, these actions result in
early afterdepolarizations and triggered firing that may ini-
tiate AF.18-21 Interruption of nerves from the GP to the PVs
may explain the frequent elimination of focal firing pro-
duced by PV isolation procedures during ablation therapy.
These findings support the role of GP activity in the onset
and perpetuation of AF, and may explain the success of early
ablation studies targeting only the GP.22
Structural and Electrical Remodeling
Once established, AF begets AF through a self-
perpetuation process called structural and electrical remod-
eling.23,24 At the structural level, AF causes atrial fibrosis,
dilatation, increased compliance, and reduced contractility.
Ultrastructural changes of myocytes lead to the so-called
dedifferentiation, because myocytes return to the fetal phe-
notype.11 At the electrical level, progressive shortening and
dispersion of refractory periods are the main changes occur-
ring during AF.
The key points regarding the pathophysiology AF ablation
are reported in Table 3.
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TABLE 3
Key Points Regarding the Pathophysiology of AF
–The pathogenesis of AF is often multifaceted. Increased atrial mass,
decreased conduction velocity, and decreased atrial refractoriness with
increased dispersion are all profibrillatory factors.
–The onset and maintenance of AF requires an event or trigger (usually
ectopic beats originating in the PVs or other anatomical structures) that
initiates the arrhythmia and the presence of a predisposing substrate
(atrial enlargement, atrial fibrosis, loss of myocardial tissue, etc.) that
perpetuates it.
–Additional factors (e.g., inflammation or autonomic tone) may also
cooperate as modulators in facilitating initiation and continuation of AF.
–Once established, AF begets AF through a self-perpetuation process
called structural (atrial fibrosis, dilatation, etc.) and electrical (shortening
and dispersion of refractory periods) remodeling.
Techniques and Technologies for AF Catheter Ablation
At present, multiple approaches for catheter ablation of
AF have been developed. The current techniques focus on
the elimination of mechanisms involved in the initiation and
maintenance of AF, which are essentially represented by trig-
gers (PVs and non-PV foci) and substrate (autonomic and
electrophysiologic). The different techniques proposed for
catheter ablation of AF include PV isolation, electrogram-
based ablation or complex fractionated atrial electrograms
(CFAEs) ablation, linear lesions, autonomic GP ablation, AF
nests ablation, and sequential ablation strategy.
PV Isolation
“PV isolation” is considered the cornerstone of current
AF catheter ablation techniques and is aimed at the electri-
cal disconnection of the PV from the adjacent LA. The PV
isolation comprises segmental/ostial PV ablation, circumfer-
ential PV ablation, and circumferential/antral PV isolation
(Fig. 2).
Segmental/ostial PV isolation
A truly segmental PV isolation requires ablation inside the
vein or very close to the output into the atrium15,25 (Fig. 2A).
It is now appreciated that ablation in the PVs themselves
needs to be avoided as much as possible, primarily due to
concern for development of PV stenosis. Therefore, the seg-
mental/ostial PV isolation technique in the strictest sense has
generally fallen out of favor. For segmental/ostial PV isola-
tion, a circular mapping catheter (CMC) of variable diameter
(15–25 mm) is inserted into the LA through a long introducer
via the transseptal route, and is positioned sequentially at the
ostia of the 4 PVs25 (Fig. 2A). Alternatively, a multielectrode
array system can be used. The ablation catheter is positioned
at the ostium of the vein on the atrial side; a series of seg-
mental lesions are then created until isolation of the vein can
be demonstrated by disappearance of the venous potentials
on the CMC (i.e., entrance block). Electrical disconnection
of the PVs can be also demonstrated by pacing from in-
side the PVs (i.e., exit block). Ablation can be performed
in sinus rhythm or during AF. The literature data display
complete agreement as to the need to achieve isolation of
all 4 PVs.
Circumferential PV ablation
Circumferential PV ablation using 3D electroanatomical
mapping was initially described by Pappone et al.26,27 Ini-
tially, the lesion set was limited to wide (>0.5 cm outside
PV ostia) circumferential lesions around and outside the PV
ostia but over time it was modified with wider (1–2 cm out-
side PV ostia) circumferential lesions (Fig. 2C). Radiofre-
quency (RF) energy is applied continuously on the planned
circumferential lines, as the catheter is gradually dragged
along the line, often in a to-and-fro fashion over a point.
Successful lesion creation at each point is considered to have
taken place when the local bipolar voltage has decreased
by 90% or to <0.05 mV. This technique, as initially de-
signed, did not involve verification of PV isolation (Fig. 2C).
Many other centers have adopted this technique, some of
which have added circular mapping to verify PV electrical
isolation.
Circumferential/antral PV isolation
The key to this technique for PV isolation is delivery of
the ablation lesions to the vestibule or “antrum” of the PV,
which is the funnel-shaped portion of the LA (or perhaps
more accurately the PV) that is proximal to the PV-LA junc-
tion or so called “ostium.” The antrum includes the entire
posterior wall and extends anteriorly to the right PVs on the
septum (Fig. 2B). Various tools, according to operator prefer-
ence, can monitor the identification of this region during the
ablation procedure. Selective pulmonary venography is used
by many centers to establish the relevant anatomy. Intracar-
diac echocardiography (ICE) offers a better definition of the
LA and proximal PV anatomy and allows localizing catheter
position.28 Computerized 3D mapping and navigation tech-
niques (Carto, NavX, etc.) are useful means to clarify the
anatomy of the region and provide a method of nonfluoro-
scopic catheter guidance. These techniques might be made
more anatomically accurate by registration with other imag-
ing techniques such as magnetic resonance (MR) or com-
puted tomography (CT). Technologies to perform “near real
time” imaging in the EP laboratory, such as with rotational
angiography, are available and might help to address some
of the shortcomings of preprocedural imaging, but to date are
still not sufficiently effective to result in widespread adoption.
The use of a CMC for PV isolation procedures has be-
come incredibly widespread. For the CMC guided ablation
technique, 1 or 2 (double Lasso technique; Fig. 2D)29 CMCs
are placed within the ipsilateral superior and inferior PVs or
within the superior and inferior branches of a common PV
during RF delivery. RF ablation is applied until absence or
dissociation of all PV potentials are documented by CMCs
within the ipsilateral superior and inferior PVs.
RF ablation catheter technologies might include standard
tip (e.g., 4 mm), large tip (e.g., 8 mm), and closed or open
irrigation. With the use of nonirrigated or closed-irrigation
ablation catheter technologies, many centers employed ICE
during lesion delivery to assess for the formation of mi-
crobubbles30 and to monitor in this way tissue overheating.31
With the use of open-irrigation ablation catheters this is no
longer relevant.
New tools and techniques to perform PV isolation
There has been development of new technologies to assist
the operator with PV isolation for AF catheter ablation.
Various balloon-based technologies have been under in-
vestigation, generally designed specifically to deliver arcs
or circumferential lesions at the PVs.32 Such technologies
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Figure 2. (A) Segmental/ostial isolation: the isolation of PVs is performed at level of the ostium (black ring) and verified by means of a CMC (blue ring)
sequentially positioned at each PV. The red dots correspond to the application of RF energy. The arrow indicates the CMC. (B) Circumferential/antral PV
isolation: the isolation of PVs is performed at level of the antrum and the CMC is moved all around the PVs and the posterior wall of LA. (C) Circumferential
PV ablation: the ablation is performed by using a 3D electroanatomical mapping and creating a circumferential lesion around each PV (1-2 cm outside
the ostium); verification of PVs isolation by means of a CMC is not strictly required for this technique. (D) Double Lasso technique: the isolation of PVs is
performed by means of continuous circular lesions around both ipsilateral PVs and verified by means of 2 CMCs placed within the superior and inferior
Pvs. CMC = circular mapping catheter; LIPV = left inferior PV; LSPV = left superior PV; RIPV = right inferior PV; RSPV = right superior PV; PV =
pulmonary vein.
have included the use of cryothermy,33-35 laser,36,37 ul-
trasound,38-40 and RF energy.41-43 Typically these tech-
nologies have employed a noncompliant balloon and have
suffered from inability to isolate the PVs proximally, par-
ticularly at the antrum, but instead achieve isolation more
distally at the ostium of the PV or even within the PV
itself.44,45 This latter issue has been the “Achilles heel” of
such balloon technologies, as the resulting lesion delivery at
such a distal location has been associated with lower effi-
cacy, by not addressing more proximal sites of triggers, and
with an increase in complications such as PV stenosis and
phrenic nerve damage. Other balloon-based technologies are
under development that would employ a compliant balloon
to address these shortcomings.37
Another new technology has been the development of
catheters with various lengths and shapes of the effective
ablation delivery region. With use of such catheters, delivery
of arcs or lines of lesions might be facilitated.46,47
Robotic technologies have been developed for use for
catheter navigation. Presently, 2 of such technologies are
available.48,49 One technology utilizes magnetic fields to nav-
igate special magnetic catheters. The magnetic field can be
manipulated at a remote workstation to direct the tip of the
catheter. A significant advantage of the magnetic catheter
is the physical property of being quite floppy, with virtu-
ally no ability to generate excessive contact force against
the myocardium to prevent a risk of perforation. This al-
lows for manipulation of the catheter without or at least with
much reduced fluoroscopic guidance. A major limitation of
this robotic technology is the inability to control additional
catheters, such as the CMC and/or the ICE catheter. The use
of this magnetic robotic technology for AF catheter abla-
tion has been reported with comparable efficacy and safety
to manual techniques.50-52 Another robotic technology that
has become available is a system that employs a deflectable
sheath controlled at a remote workstation. The primary ad-
vantage of this system is the ability to use standard catheters
rather than specialized catheters as with the magnetic robotic
system. However, this system does not offer the safety of
the magnetic catheters with regards to potential for excessive
forces to the myocardium, so the risk of perforation remains
an issue. Reports from centers with extensive experience has
demonstrated comparable results to manual methods and re-
duced fluoroscopy times.53,54
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Electrogram-Based Ablation or CFAEs Ablation
Different patterns of electrograms have been targeted dur-
ing radiofrequency catheter ablation of AF.21,55-64 Among
these, CFAEs have been most widely studied. In the initial
report by Nademanee et al., the definition of CFAE included:
(1) atrial electrograms composed of 2 deflections or more,
and/or perturbations of the baseline with continuous deflec-
tions of a prolonged activation complex over a 10-second
recording period, and (2) atrial electrograms with very short
cycle lengths (≤120 ms) averaged over a 10-second record-
ing period. Intraoperative mapping of AF has shown that
CFAEs are found mostly in areas of slow conduction or at
points where the wavelets turn around at the end of arcs of
functional block. Such CFAEs have heterogeneous spatial
and temporal distribution. Recent studies have attempted to
target these CFAEs in order to terminate and prevent recur-
rence of AF.55,56,61-63,65-67
In the study by Nademanee et al., regarding 121 patients
with AF (57 paroxysmal), CARTO mapping of both atria was
performed during spontaneous or induced AF. CFAEs were
identified using bipolar recordings filtered at 30 to 500 Hz and
defined by the presence of voltage ≤ 0.15 mV.55 RF ablation
of the area with CFAEs was performed in an attempt to elimi-
nate the CFAEs. According to this report, 92 (76%) of the 121
patients were free of arrhythmia at 1-year follow-up. How-
ever, other studies have shown conflicting results with some
improvement or no improvement when ablation of CFAEs
alone or in combination with PV isolation is performed, in
patients undergoing AF ablation.56,61-63,65-67 According to a
recent meta-analysis, the addition of CFAE ablation to PV
antral isolation increases the rate of sinus rhythm mainte-
nance in patients with persistent and long-lasting persistent
AF, but does not provide supplemental benefit in patients
with paroxysmal AF.67 Therefore, further randomized stud-
ies are needed to clarify the real value of CFAE ablation in
patients with AF.
Linear Lesions
Linear lesions were used initially intraoperatively with
the aim of preventing the multiple reentrant wavelets that
sustain AF. It is not surprising that catheter-based ablation
procedures pursued a similar strategy. The goal of linear
lesions is the achievement of bidirectional conduction block.
Despite the use of irrigated tip ablation catheters with 3D
anatomical guidance, lesion creation remains challenging.68
Linear lesions have been reported to be associated with
conversion of AF either directly to sinus rhythm or to atrial
tachycardia (AT), further demonstrating that such lesions
may at least in some patients deeply modify the substrate for
AF.69,70 Most of these ATs are macroreentrant and require
linear lesions to be treated.71 Such organized tachycardias
may be observed during the index procedure or emerge upon
follow-up. Although complete linear lesions can terminate
such organized tachycardias, the development of a gap in
conduction block along such lines has the potential for a
proarrhythmic effect and can facilitate sustained reentry.72
For patients in whom atrial flutter has been previously
recorded clinically as well as those in whom right atrial
flutter is inducible after PV isolation, ablation of the right
atrial cavo-tricuspid isthmus73 may be appropriate but on
long-term follow-up may be of limited added value beyond
PV isolation alone.74,75 Ablation of the posterolateral mitral
isthmus (to the inferior pole of the left PV antrum) has been
widely deployed in patients with persistent AF.69,76,77 One
limitation of the mitral isthmus ablation is that it can require
supplemental radiofrequency applications in the distal CS
with its intrinsic safety concerns before conduction block is
achieved. A number of approaches have been proposed to
overcome this requirement, including balloon occlusion of
the CS to reduce the heat sink effect of the CS blood flow
during endocardial ablation78 and modification of the line to
a more supero-lateral trajectory.
With wide area circumferential PV antral isolation ap-
proach, the distance between the contralateral encirclements
is greatly reduced posteriorly. Thus, an LA roof line (which
can be created sufficiently superiorly to minimize ablation
adjacent to the esophagus) can be achieved with a short trans-
verse lesion connecting the 2 encirclements. More recently
the creation of a second transverse linear lesion between the
inferior poles of the contralateral encirclements has been de-
ployed in order to complete a box isolation of the posterior
LA wall.79 This latter technique has the advantage of isolat-
ing a large area of high frequency activity where triggers and
drivers are more likely to occur than other parts of the atria.
Supplemental linear ablation on the anterior wall of the LA
appears to be of lesser potential impact.80
Catheter Ablation of Left Atrial GP
Autonomic influences in the heart are produced by the
extrinsic (central) and intrinsic cardiac autonomic nervous
systems. The intrinsic cardiac autonomic nervous system
contains clusters of autonomic GP located in epicardial fat
pads on the left and right atria (superior left GP, inferior left
GP, anterior right GP, inferior right GP) and in the ligament
of Marshall (Marshall tract GP).81-83 In patients with AF,
endocardial high-frequency stimulation (HFS, cycle length
50 ms, 12 Volt actual output, 10 ms pulse width) produces
a positive vagal response (transient AV block during AF
and hypotension), allowing the identification and localiza-
tion of left atrial GP. These GP may represent a target of AF
ablation.
For endocardial GP ablation, RF energy should be applied
to each site exhibiting a positive vagal response to HFS.83,84
HFS is repeated after each RF application. If a vagal response
is still present, RF energy is reapplied until the vagal response
is eliminated. Elimination of the vagal response to HFS at
each GP generally requires 3-10 RF applications (usually
30-35-40 Watts for 30–40 seconds but less when close to the
esophagus).
In a population of 63 patients with paroxysmal AF under-
going ablation of the left atrial GP followed by PV antrum
isolation, GP ablation alone (prior to PV antrum isolation)
decreased the occurrence of PV firing from 47 of 63 pa-
tients (75%) before GP ablation to only 9 of the 63 patients
(14%) (P < 0.01) after GP ablation.83 PV antrum isolation
was then performed, which eliminated PV firing in the re-
maining 9 patients (0/63 patients). The description in this and
earlier studies of the elimination of PV firing by PV isolation,
without targeting the sites of firing,85 may be explained by
the interruption of the axons extending from the GP to the
PV myocardium. A similar relationship is present between
CFAE ablation86 and GP ablation. GP ablation alone often
eliminates the majority of CFAE, despite ablating a much
smaller area than the overall CFAE area. CFAE ablation may
896 Journal of Cardiovascular Electrophysiology Vol. 23, No. 8, August 2012
eliminate much of the fractionation by ablating the axons
without ablation of the GP cell bodies.
Ablation of AF Nests Guided by Real-Time Spectral
Mapping in Sinus Rhythm
Pachon et al. have developed a system for real-time spec-
tral mapping using fast Fourier transform in sinus rhythm.86
This mapping strategy identifies sites in which the unfiltered,
bipolar atrial electrograms contain unusually high frequen-
cies, namely fibrillar myocardium or the so-called AF Nest.
The investigators successfully targeted biatrial AF Nests,
without intentional PV isolation, as a novel approach for
AF ablation. Oh et al. compared CFAE sites and AF Nests
in an animal model of vagally mediated AF and concluded
that these sites did not share identical anatomical locations.87
Typically for AF Nest ablation, RF delivery for 20–30 sec-
onds abolishes the high-frequency potentials normalizing the
spectrum. Arruda et al. evaluated the adjunctive role of AF
Nest ablation to antral PV isolation and SVC isolation in a
prospective randomized study. The adjunct of AF Nest abla-
tion resulted in a 10% decrease of recurrence as compared
to conventional antral PV isolation and superior vena cava
isolation.88
Sequential Ablation Strategy
A stepwise approach has been recently developed in
patients with long-lasting persistent AF with different se-
quences that target multiple atrial areas.89 The endpoint of
the sequential ablation strategy is termination of AF. This
can be achieved by passing directly from AF either to sinus
rhythm or, more commonly, to AT, which is then mapped and
ablated. The first step consists in PV isolation using antral
isolation. As only 12% of AF will stop at that stage, the sec-
ond step is frequently needed. It requires ECG-guided abla-
tion targeting continuous electrical activities, focal sources,
areas with temporal gradient, etc. The last step uses linear
lesions and is used in case of persisting AF/AT after the first 2
steps. The mitral isthmus line is deployed after the roof line
as a last resort given the difficulties observed in achieving
a complete block. Once sinus rhythm has been restored, PV
isolation and linear lesions are checked for completeness and
areas re-ablated if needed. It should be emphasized that this
approach represents an extensive procedure associated with
significant risks and requires careful and individualized risk–
benefit assessment. However, it is associated with unprece-
dented success rate in long-lasting AF, particularly when AF
termination is achieved during the index procedure.
Future Technologies
In order to improve permanent transmural lesion forma-
tion, contact force sensing technology (Biosense Webster
and Endosense SA) is currently under clinical investigation.
The contact force sensor integrates within the distal tip of a
conventional mapping and ablation catheter, providing real-
time catheter tip-to-tissue contact feedback. Preliminary re-
sults using the Endosense catheter demonstrate feasibility
and safety in using this new technology for PV isolation.90
Several ongoing studies will determine whether the addi-
tion of contact force measurement during AF ablation will
result also in improved procedural outcome. An alternative
means of contact force assessment utilizes local impedance
changes between catheter tip and cardiac tissue. The software
TABLE 4
Key Points Regarding the Techniques and Technologies for AF Catheter
Ablation
–PV isolation is the cornerstone of current AF catheter ablation
techniques. A CMC is the most widespread and reliable method to assess
effective PV isolation.
–PV isolation may be performed at different levels, but nowadays it is
performed preferentially at level of PV antrum, to include in the lesion
important anatomical structures for the initiation and maintenance of AF
(LA posterior wall, GP, rotors, etc.).
–Nonparoxysmal AF patients necessitate a more extensive ablation
protocol. Adjuvant ablation of the CFAEs increases the success rate of
PV isolation in these patients.
–The incremental therapeutic value of other ablation strategies, such linear
lesions, GP ablation, and stepwise approach remains to be established.
–New technologies (balloon-based, robotic, contact-force sensing
technologies, etc.) are being developed with the principal aim of
increasing the effectiveness and safety of catheter ablation of AF, while
reducing the operator dependency.
integrates with the Ensite NavX electroanatomical mapping
system and initial animal and human studies have shown
its clinical utility during mapping and ablation within the
LA.91,92
The ability to register real-time in-tissue temperature dur-
ing ablation could potentially facilitate better lesion forma-
tion. Using microwave radiometry, very early in-human data
demonstrate a correlation between in-tissue temperature and
lesion transmurality. Future studies are needed to assess the
system’s feasibility during AF ablation.
The remote magnetic mapping and ablation system
by Magnetecs promises real-time catheter maneuverability
within a magnetic field of 1.5 Tesla. The system uses 8 elec-
trical magnets that can be switched off. Hence, no magnetic
shielding of the examination room is needed. Studies are
under way to test the system’s mapping capabilities within
humans.
The Amigo robotic arm by Catheter Robotics can be
mounted on any conventional examination table and facil-
itates remote-controlled movement of mapping and ablation
catheters. The system is available in Europe and can be inte-
grated with any electroanatomical mapping system. Clinical
data are limited with 1 trial currently recruiting patients to
assess the system’s ability to navigate and map within the
human heart.
A new electroanatomical mapping system is currently be-
ing developed that uses a basket-shaped mapping catheter
to facilitate acquisition of several thousand mapping points
within several minutes. Initial clinical data indicate that the
system is able to map complex left atrial arrhythmias in
humans.
The key points regarding the techniques and technologies
for AF catheter ablation are reported in Table 4.
Endpoints of Catheter Ablation for Atrial Fibrillation
The principal procedural endpoints used for catheter ab-
lation of AF depend on the type of AF being treated. End-
points include completion of a predetermined lesion set,93
termination of AF during ablation,89 and noninducibility of
AF following ablation.94,95 There is still debate surround-
ing the predictive value of such endpoints, in particular AF
termination.
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TABLE 5
Ablation Sites and Ablation Endpoints of the Different Techniques for Catheter Ablation of AF
Ablation Technique Ablation Site Ablation Endpoints
Segmental/ostial PV isolation PV ostium Complete elimination or dissociation of PV
potentials assessed by a CMC
Circumferential PV isolation 1–2 cm outside PV ostium Abatement of local bipolar voltage by 90% or <0.05
mV within encircled areas
Antral PV isolation PV antrum Complete elimination of PV potentials with
isolation of all PVs and posterior wall of LA
assessed by a CMC
CFAEs ablation LA areas where CFAEs are recorded Complete elimination of CFAEs Termination of AF
Noninducibility of AF
Linear lesions LA roof and mitral isthmus Creation and demonstration of line of complete
block
Autonomic GP ablation GP located around PVs Abolition of vagal reflexes induced by HFS
AF Nest ablation Local high frequency activity or focal and
centrifugal spread of activation or frequency areas
Abolition of these high sites with temporal gradient
between 2 dipoles
Other structures and thoracic veins CS, LA appendage, superior vena cava, persistent
left superior vena cava, vein of Marshall
Complete elimination or dissociation of other
structures or thoracic veins
In patients with paroxysmal AF, it is possible that the
termination of AF during ablation is coincidental. In these
patients noninducibility seems to be associated with an im-
proved outcome.95,96 However, there is no current consensus
on the definition of noninducibility and the standardization
of the induction protocol used. Furthermore, it is likely that
the noninducibility of AF might identify a subgroup of pa-
tients who have less severe atrial disease and therefore more
likely to have a successful outcome. For patients with persis-
tent and long-lasting persistent AF, the procedural endpoint
is also unclear. Although restoration of sinus rhythm by ab-
lation, without the use of antiarrhythmic drugs or DC car-
dioversion, appears to be an intuitively ideal endpoint, this is
not always achievable and results regarding clinical outcome
are controversial.97-99 Until more data are available, comple-
tion of a predetermined lesion set incorporating PV isolation
remains the basic procedure.100 Verification and completion
of ablation linear lesion sets is fundamental to minimizing
proarrhythmia and arrhythmia recurrence. The ablation end-
points of the principal ablation approaches previously dis-
cussed are summarized below and in Table 5.
PV Isolation
There is consensus that electrical PV isolation is the opti-
mal endpoint for ablation targeting the LA–PV junction and
is now generally incorporated as the initial lesion set in AF
ablation strategies.101,102 The most objective procedural end-
point is absence or dissociation of PV potentials recorded
from a CMC positioned just inside the PV28,29,103,104
(Table 5). Many consider the same endpoint of electrical
PV isolation optimal for wide area circumferential PV abla-
tion. However, reduction of local bipolar amplitude with low
peak-to-peak bipolar potentials (≤ 0.1 mV) inside the encir-
cled area as well as local endocardial activation time >30 ms
between contiguous points lying in the same axial plane on
the external and internal side of the line, are still suggested
by some authors as a suitable endpoint in order to avoid the
necessity for a CMC26 (Table 5). Exit block into the LA can
also be proven with pacing maneuvers from inside the PV,
but this is not routinely applied. This is due to the technical
difficulty of ensuring pacing capture of the muscle sleeves
inside the vein without far-field capture of the left or right
atrium.
The role of intravenous adenosine as an adjunct to prove
permanent abolition of PV conduction has been suggested105
and is part of an ongoing prospective study.106 As an addi-
tional endpoint, nonexcitability of bilateral circumferential
lines following PV isolation has been introduced.107,108
Electrogram-Based Ablation or CFAEs Ablation
Endpoints for ablation of sites of CFAEs include:
(1) complete elimination of the areas with CFAEs, (2) conver-
sion of AF to normal sinus rhythm for both paroxysmal AF
and persistent/long-lasting persistent AF patients, (3) con-
version of AF to an organized atrial tachyarrhythmia (AT
or flutter), and (4) noninducibility of AF in paroxysmal AF
patients55,56,61-63,65-67 (Table 5).
The ablation typically begins at the sites where CFAEs
have the shortest local A-A interval. Such sites are unfortu-
nately ubiquitous in persistent AF. It is not known whether
ablation of all such sites is necessary or if it is possible to
target specific locations and thereby limit the extent of un-
necessary ablation and resultant tissue damage. Irrespective
of electrogram complexity, ablation all along some structures
like the CS, LA appendage,109 and septum may also have an
impact on AF perpetuation.
Importantly, after “defragmentation” and prior ablation
(PV isolation and eventually linear lesions), electrograms
may become discrete or organized, allowing a dominant rate
(frequency) and specific activation sequence to be identi-
fied. In such situations, parameters other than fragmentations
may be used. Local high-frequency activity or focal and cen-
trifugal spread of activation or sites with temporal gradient
between 2 bipoles of conventional mapping catheter (rep-
resenting local circuit, “rotor” or “AF nest”) are potential
targets for ablation.110
Linear Lesions
In patients with persistent or long-lasting persistent AF,
the use of adjunctive linear ablation, mainly at the level of LA
roof and mitral isthmus, has been associated with higher suc-
cess rates.95,111,112 The endpoint should be a complete line of
linear lesions76,77,113,114 because incomplete lesions are as-
sociated with recurrence of atrial arrhythmias.72,115,116 The
electrophysiological endpoint should therefore be demon-
stration of bidirectional line of block76 (Table 5). A complete
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LA roofline may be demonstrated by activation progressing
in a caudal-cranial direction on the posterior wall during left
appendage pacing.77 A complete mitral isthmus line may
be demonstrated by an inversion of CS activation sequence
from distal–proximal to proximal–distal during pacing from
the left appendage.76
Autonomic GP Ablation
Autonomic GP located around PV can be identified by
HFS. HFS at these sites leads to induction of bradycardia
or AV block due to increased vagal tone. Abolition of in-
ducible vagal reflexes has been proposed as an endpoint of
GP ablation117 (Table 5). It is unclear whether GP should
be specifically targeted given that these sites may be con-
comitantly ablated in the course of above-described ablation
targets. Most centers still do not specifically target such GP,
although these may be affected especially when extended
ablation approaches are introduced.
CS and Other Thoracic Veins Ablation
Similar to triggers arising from the muscle sleeves sur-
rounding the PVs, rapid atrial activity from the musculature
of the CS may be a driver for persistent or long-lasting persis-
tent AF. The same electrogram-based approach as discussed
above can be applied to the CS.118
Other potential triggers, such as superior vena cava and
persistent left superior vena cava,119,120 can be electrically
isolated by ablation technique and endpoints similar to PV
isolation121 (Table 5).
The key points regarding the endpoints of catheter ablation
for AF are reported in Table 6.
Patient Management Pre-, During, and Postablation
Preablation Management
Anticoagulation
Effective anticoagulation therapy is often necessary be-
fore an ablation procedure for AF. The modalities and du-
ration of preablation anticoagulation therapy are reported in
detail later.
Other drugs
Drug treatment for nonarrhythmic indications is generally
continued. There is no consensus with regard to discontin-
uing antiarrhythmic drugs (AADs), although to avoid con-
founding ablation effects with AADs effects, all AADs with
the possible exception of amiodarone should be discontin-
ued at least 4 half-lives in advance. However, if symptomatic
arrhythmias demand, effective AADs may be continued.
Transesophageal echocardiogram
A preablation transesophageal echocardiogram (TEE) is
used to rule out the presence of a LA thrombus, and should
be considered a supplementary and backup strategy to con-
tinuous effective anticoagulation leading up to the ablation
procedure. It should be performed shortly before the ablation
procedure and without an intervening window in effective
anticoagulation. In many EP laboratories, TEE is performed
only in patients presenting with AF and off anticoagulation
therapy.
Other imaging studies
Imaging to define the cardiac substrate could include es-
tablishing the presence and extent of coronary artery disease
(if present) and left ventricular size and function. A transtho-
racic echocardiogram before the procedure is useful and al-
lows measurement of chamber size and ejection fraction. LA
size is an important determinant of rhythm outcome after ab-
lation and may influence the selection of ablation strategies.
The most widely used measure, single-plane dimension from
the parasternal long-axis view, correlates modestly with LA
volumes. Estimation of LA volume from multiple 2-D imag-
ing planes or by volumetric analysis of MR or CT images
may be preferable and more accurate. Evaluation of LA emp-
tying and systolic function (ejection fraction) is not part of
most standard imaging routines but may have an important
role in evaluating the long-term impact of ablation on LA
function.
An MR or contrast-enhanced spiral CT scan is obtained
as a baseline both for comparison and for formulation of
an ablation strategy with variable PV anatomy.122 In some
laboratories, the ablation is performed with MR or CT image
integration. In such situations, both the underlying rhythm
and ventricular rate at the time of acquisition are important in
order to make effective use of the 3D images.123 Preliminary
data indicate that preprocedure delayed enhancement MR
may be useful in predicting procedural outcome.124
Informed consent and preablation fasting
As for any ablation, an informed consent and appropriate
preparation including at least 6 hours of fasting leading up to
the procedure are necessary.
Management During Ablation
Sedation/anesthesia
Conscious sedation using midazolam combined with anal-
gesia using fentanyl is used in ablation procedures of less
complex arrhythmias and can also be applied during AF
ablation. However, conscious sedation is often inadequate
during AF ablation, due to long procedure times, pain during
RF energy applications, and the need to limit patient motion
during the procedure. Therefore, general anesthesia is widely
used during AF ablation. General anesthesia may reduce the
prevalence of PV reconnection during repeat ablation when
compared with conscious sedation.125 Alternatively, deep se-
dation during continuous infusion of propofol has evolved as
a third sedation alternative. This strategy can achieve pain-
less deep sedation without the need for intubation and general
anesthesia, and can be guided by the electrophysiologist.126
Anticoagulation
The intensity of anticoagulation during the AF ablation is
of critical importance and is described in chapter 6.
AADs/electrical cardioversion
Many investigators choose to perform the AF ablation
procedure off AADs. The procedure can be performed during
either sinus rhythm or AF. In selected cases, AADs may be
administered intravenously when sinus rhythm is desired.
Alternatively, electrical cardioversion can be applied when
sinus rhythm is the preferred rhythm during specific parts of
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TABLE 6
Key Points Regarding the Endpoints of Catheter Ablation for AF
–Primary targets of AF ablation are PVs and/or PV antrum.
–Primary goal is complete and permanent electrical isolation of PVs.
–Careful identification of PV ostia is essential to avoid ablation within the PVs.
–Ablation of focal extra-PV triggers (superior vena cava, vein of Marshall, CS, LA appendage) is recommended.
–In patients with paroxysmal AF, electrical isolation of the PVs is sufficient. In patients with persistent and long-lasting persistent AF, additional lesions
are usually required (CFAEs ablation, linear lesions, GP ablation).
–For additional linear lesions (LA roof, mitral isthmus, anterior left septum), verification of line completeness demonstrated by bidirectional block is of
fundamental importance to minimize arrhythmia recurrence.
–Ablation of the cavotricuspid isthmus is recommended only with history of typical atrial flutter or inducible cavotricuspid isthmus dependent atrial flutter.
–No consensus on other endpoints exists: use of intravenous isoproterenol to unmask focal extra-PV triggers, role of intravenous adenosine as an adjunct
to prove permanent abolition of PV conduction, AF termination during ablation and AF inducibility postablation.
the procedure, e.g., verification of conduction block across
linear ablation lines and confirmation of PV isolation.
Postprocedural Management
The immediate postprocedural management consists of
continuing and maintaining anticoagulation, maintaining
hemostasis at puncture sites, and supportive treatment. Va-
gal episodes remedied by fluid infusion and/or atropine are
not uncommon; however, pericardial tamponade must be ex-
cluded in patients with postprocedural hypotension. Peri-
carditic discomfort may occur during the first 3–5 days,
sometimes accompanied by a mild and self-limited febrile
syndrome. Aspirin is usually sufficient treatment although
uncommonly, continuing symptoms and a nonresolving peri-
cardial effusion may require the administration of systemic
steroids. The later occurrence (6–10 days postablation) of a
febrile state with or without neurological symptoms should
prompt suspicion of an atrio-esophageal fistula and lead to a
contrast-enhanced spiral CT to exclude the diagnosis.
Many centers now perform AF ablation while continuing
therapeutic anticoagulation with warfarin.127 In this case, oral
warfarin anticoagulation can simply be continued after ab-
lation. For other practical aspects regarding anticoagulation
after AF ablation, see later.
Rhythm outcome
Estimating the burden of AF, both symptomatic and
asymptomatic, is the key to determining the outcome of
the procedure. The ideal outcome would be a zero residual
burden with no atrial flutter or AT. The absence of symp-
toms may not correspond to the stable restoration of sinus
rhythm, probably due to ablation-induced denervation or be-
cause of the absence of symptoms at baseline. The accuracy
of estimating AF burden depends chiefly upon the duration
of ECG recording (Table 7).128-135 Many laboratories use
a clinical definition of successful ablation to mean the ab-
sence of symptomatic tachycardia, as well as the absence
of documented AF during periodic follow-up visits as well
as on periodic 24–48-hour Holter recordings, typically at 1,
3, and 6 months after the ablation. An event recorder may
be used to evaluate symptoms not elucidated by the above
tests. However, extending the duration of Holter tracings to
7 days has been shown to enhance the sensitivity of detect-
ing recurrent AF.136 Another approach has been to monitor
periodic, even daily, transtelephonic ECG recordings supple-
mented by ECG transmission during symptomatic episodes,
although the correlation to AF burden may be difficult to de-
termine.132 Finally, more and more implanted devices have
sufficient memory and accurate arrhythmia recognition soft-
ware to provide probably the most accurate measurement of
AF burden possible, but of course only in a limited patient
population.137,138 From a clinical standpoint, when success
is defined as the restoration of stable sinus rhythm, this as-
sumes the elimination of (sustained) ATs as well, whether
reentrant (flutters) or nonreentrant.
Owing to the difficulty of clinically measuring the AF
burden, the temporal evolution of arrhythmias in ablated pa-
tients has not been clearly determined. Although some groups
have re-ablated patients as soon as they develop recurrent AF,
others have advocated waiting for 1–3 months with or with-
out adding AADs treatment in the interim period. An early
re-ablation may result (unnecessarily) in a higher incidence
of local puncture site complications, a longer hospital stay,
and the risks of an additional left-sided procedure. About
30–50% of patients with documented or symptomatic recur-
rences during the first 3 months after an AF ablation have
no further AF or flutter even without additional ablation.
However, early AF recurrences do portend a worse long-
term outcome, and merit heightened awareness of later AF
occurrences (see later).
AADs therapy
It has been demonstrated in a prospective randomized
trial that treatment with AADs during the first 6 weeks
after AF ablation reduces the incidence of clinically sig-
nificant atrial arrhythmias and need for cardioversion or
hospitalization for arrhythmia management.139 However,
systematic AADs therapy did not reduce late arrhythmia re-
currence during longer-term follow-up in the same popula-
tion.140 Alternatively, AADs are stopped 4 half-lives before
ablation and not restarted unless symptomatic or sustained
recurrences occur. There are no guidelines for discontinuing
AADs therapy after AF ablation. Depending upon the risk
of recurrence and the accuracy of determining residual ar-
rhythmias, trial of discontinuation may be offered after 3–6
arrhythmia-free months. According to a recent paper, tran-
sient use of small amounts of corticosteroids (prednisolone
0.5 mg/kg/day) shortly after ablation (first 3 days) may be
effective and safe for preventing both immediate and late
AF recurrences (14 months follow-up).141 Other drugs such
as angiotensin-converting enzyme inhibitors, angiotensin re-
ceptor blockers, statins, and polyunsaturated fatty acids may
potentially prevent AF by a variety of mechanisms, includ-
ing anti-fibrotic, anti-inflammatory, and anti-oxidant effects.
However, the efficacy of these drugs in reducing postablation
arrhythmia recurrences has yet to be demonstrated.142
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TABLE 7
Incidence of Asymptomatic AF in Postablation Patients
Authors Total number of patients Number of patients with asymptomatic AF (%) ECG detection method
Oral et al.128 53 1 (2%) Transtelephonic ECG monitoring
Hindricks et al.129 108 20 (18%) 7-day Holter monitoring
Senatore et al.130 72 8 (11%) Transtelephonic ECG monitoring
Neumann et al.131 80 11 (14%) External loop recorder
Vasamreddy et al.132 10 2 (20%) Mobile continuous outpatient telemetry
Klemm et al.133 80 7 (9%) Transtelephonic ECG monitoring
Verma et al.134 86 2 (2%) Pacemaker/ICD memory
Steven et al.135 37 0 (0%) Pacemaker/ICD memory
Note: Only the incidence of asymptomatic episodes is reported.
Late surveillance
Echocardiographic monitoring is useful to detect im-
provement in left ventricular function and assess reductions
in LA size after ablation.143,144 In the light of the high rates
of symptomatic PV stenosis/occlusion in the early days of
ablation targeting the PVs, routine MR or CT imaging was
advocated at 3–6 months following the ablation. However,
improvements in intra-procedural imaging as well as strate-
gic changes in placing ablation lesions more remote from
the PV ostia, has resulted in significant reductions in PV
stenosis rates. Furthermore, about 80% of PV stenoses, in-
cluding most single PV occlusions, are asymptomatic.145
Consequently, routine imaging with MR or CT is often re-
stricted to patients with suggestive symptoms. Finally, a sig-
nificant risk of very late AF recurrence has been reported
in several series.146,147 It is therefore advisable to maintain
periodic surveillance for arrhythmia recurrence at 6- or 12-
month intervals, even in patients who are free of arrhythmias
during the initial year following ablation.
The key points regarding patient management pre-, dur-
ing, and postablation are reported in Table 8.
Periprocedural and Long-Term Anticoagulation
Stroke is by far the most serious adverse consequence of
AF, and concern about stroke prevention pervades all deci-
sion making related to management of AF, including abla-
tion. Although the primary motivation for PV isolation pro-
cedures is to reduce symptoms, nonetheless, stroke preven-
tion needs to be considered before, during and after ablation
procedures for AF.
Preablation Anticoagulation and TEE
Because AF ablation involves not only cardioversion in
many patients and the introduction of foreign bodies into
the left heart, but also the possibility of a lapse in antico-
agulation during sheath removal, the importance of prepro-
cedural anticoagulation is well accepted. However, there are
many potential strategies and very little data to guide best
practices.
Anticoagulation strategies prior to ablation procedures in
high risk patients reflect guidelines for the care of patients
with AF in general. Patients with CHADS2 scores of 2 or
higher should be anticoagulated in any case, to an INR of 2–3
for at least 3 weeks prior to ablation; if warfarin is stopped
prior to the procedure, enoxaparin or heparin may be used
for “bridging.” There is little consensus regarding the need
for anticoagulation in low risk patients. Recent observational
studies suggest that a strategy of performing ablation with
a therapeutic INR may reduce the risk of ablation-related
thromboembolism.127,148,149 This strategy has the theoretical
advantage of eliminating the lapse in anticoagulation during
sheath removal, and has been shown to be associated with
a low rate of bleeding complications and of periprocedural
stroke. The impact of new oral anticoagulants has not been
studied in this application.
Many centers routinely perform TEE prior to ablation
to exclude the presence of thrombus in high risk patients,
particularly in those with persistent AF. Other strategies to
assess the presence of thrombus, such as CT angiography,
or intra-procedural ICE, may be reasonable but have not
been rigorously compared to TEE, which is the current gold
standard. There is little consensus in low risk patients, or
those with paroxysmal AF. A recent paper suggested that
the incidence of intracardiac thrombus was low in ablation
candidates (0.6%), but increased with increasing CHADS2
score, history of heart failure and left ventricular ejection
fraction <35%.150
Anticoagulation During the Ablation Procedure
In the updated worldwide survey of catheter ablation for
AF, a 0.94% incidence of stroke or TIA was reported,151
however an 11–14% incidence of cerebral emboli were ob-
served following catheter ablation in 2 recently published
studies.152,153 Major bleeding complications such as tampon-
ade, hemothorax, and groin complications such as pseudo-
aneurysm or AV fistula totaled 2.3%.151 Femoral hematomas
are more common, up to 8%,154 and may prolong hospi-
talization or produce a short period of disability. Achieving
the lowest possible thromboembolic complication rate while
maintaining an acceptably low bleeding complication rate is
the goal of intra-procedural anticoagulation. Thrombus can
form within sheaths or on guidewires and catheters, as ob-
served by ICE, particularly in patients with persistent AF,
dilated atria, and spontaneous echo contrast.155 To prevent
thrombus formation within the sheaths, it is common sense to
flush them intermittently or use continuous irrigation, which
may be more reliable. Since the capacity of the inner lu-
men for blood is larger without a catheter in place, it may
be beneficial to leave catheters in sheaths while in the LA.
Endocardial RF catheter ablation may disrupt endothelial in-
tegrity and expose a nidus of interstitial tissue, which may
promote thrombus formation. Char may form on the elec-
trodes of the ablation catheter if temperatures exceed 100◦C
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TABLE 8
Key Points Regarding Patient Management Pre-, During, and Postablation
Preablation
–Effective anticoagulation often necessary. TEE recommended to rule out an LA thrombus in patients with persistent/long-lasting persistent AF and/or
at high thromboembolic risk (see next chapter).
–No consensus with regard to discontinuing AADs.
–MR or CT scan important for comparison and for formulation of an ablation strategy with variable PV anatomy.
During Ablation
–Conscious sedation, deep sedation, jet ventilation, and general anesthesia are alternative methods for patient sedation during AF ablation.
–The intensity and the type of anticoagulation protocol are of key importance (see next chapter).
Postablation
–Continuation and maintenance of anticoagulation crucial (see next chapter).
–Ambulatory ECG monitoring with 1 of the different ECG detection methods strongly recommended in order to assess the correspondence between
symptoms and arrhythmia and to discover asymptomatic episodes of AF.
–No consensus exists for continuing/discontinuing AADs after AF ablation. The use of AADs in the first period after ablation reduces the recurrence
rate of early arrhythmias but not the incidence of late arrhythmias.
–The use of ACE inhibitors, statins, and PUFAs does not appear associated with a reduction of arrhythmia recurrences.
–MR or CT imaging at 3–6 months not recommended routinely but only for patients with symptoms suggestive for PV stenosis.
at the electrode–tissue interface that may increase the risk
of thrombus formation. A sudden impedance rise during RF
energy delivery may indicate the development of char and
should prompt withdrawal and inspection of the catheter tip.
A catheter tip with open irrigation appears to reduce the risk
of char and thrombus formation by cooling the electrode-
tissue interface.156
Unfractionated heparin, delivered by weight/time-based
nomograms and/or monitored by frequent measurement of
activated clotting time (ACT), is typically given during the
ablation procedure, even in the presence of a therapeutic
INR (thrombus may form in the right atrium with similar
frequency as it does in patients with an INR <2.0). Ex-
changing short vascular access sheaths for transseptal sheaths
should be preceded by careful flushing and heparin delivery
should be considered at this point rather than after transseptal
puncture, particularly in patients with a higher risk of throm-
boembolism. The target intensity of anticoagulation is not
standardized among experienced investigators, and may vary
according to several factors, for example, patient age, type
of ablation procedure, catheter used, and energy source. Ob-
servational studies have shown using ICE that the incidence
of visualized thrombus markedly decreased with an increase
in target ACT from 250–300 to >300 seconds.155,157 Many
experienced operators instruct their patients to maintain a
therapeutic INR, as it may be easier to achieve and maintain
target ACT values and may reduce the risk of stroke. The risk
of major bleeding complications does not appear to increase
using this strategy.149,154 Additionally, management of car-
diac tamponade appears to be equally safe in patients with
a therapeutic INR, but reversal agents such as fresh frozen
plasma or factor IX should be readily available during the
procedure if a therapeutic INR is to be maintained.158
Postablation Anticoagulation
No universally accepted recommendations exist for an-
ticoagulation therapy after successful ablation of AF. Due
to the high risk of thromboembolism in the early postpro-
cedural period,159 in the many centers, warfarin therapy is
started in all patients either the same evening of the ablation
procedure or the next morning. In the initial period, LMWH
(e.g., enoxaparin at a dosage of 0.5–1.0 mg/kg twice a day)
is often given as bridging therapy by starting 3–4 hours af-
ter the ablation.28,160 Less frequently, heparin is administered
intravenously until the day after the procedure, starting about
3 hours after sheath removal at a rate of 1,000 IU/h.160-162
Thereafter, LMWH is administrated until the INR is ≥2.
Warfarin is usually continued for at least 3 months.
After this period the anticoagulation strategy is contro-
versial. There have been several reports indicating that a low
rate of stroke may occur in patients with successful ablation
who do not receive anticoagulation.159,162-166 However, these
studies have 2 major limitations: (1) they are observational,
retrospective, and not randomized; and (2) most enrolled few
patients at high thromboembolic risk. The reasons for contin-
uing anticoagulation after ablation mainly concern the risk of
long-term recurrence146,147,167-177 and in particular, the risk
of asymptomatic recurrences.128-135 Furthermore, it is gen-
erally accepted that there is a continuing risk of stroke in pa-
tients receiving AADs therapy even if it appears that therapy
has eliminated AF recurrences. Therefore it would appear
to be prudent at this point to recommend that long-term an-
ticoagulation be continued in patients even after apparently
successful ablation. The use of anticoagulation requires an
assessment of stroke risk178 and bleeding risk as well as pa-
tient values. Aspirin is generally considered a poor substitute
for oral anticoagulation. New anticoagulants such as dabiga-
tran, which is easier to use than warfarin, more effective and
associated with fewer life-threatening bleeds make the deci-
sion to continue an anticoagulant after apparently successful
ablation more attractive.179
The key points regarding periprocedural and long-term
anticoagulation are reported in Table 9.
Peri-Procedural and Late Complications
Recognition of complications related to AF ablation can
help minimize risk. Overall, the rate of major complications
ranges from 0.8% to 5.2% in recent studies.151,169,180-187 The
incidence, causes, clinical presentation, diagnostic tools, pre-
ventive and therapeutic measures of each of these complica-
tions are summarized in Table 10. Death occurs, as a com-
plication of AF ablation, in 1 of 1,000 patients.188 The most
frequent causes of death are cardiac tamponade, stroke, and
atrio-esophageal fistula.189
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TABLE 9
Key Points Regarding Periprocedural and Long-Term Anticoagulation
Preablation
–In patients at moderate to high risk of stroke, anticoagulation with a Vitamin K antagonist (INR 2-3, target 2.5) or a new anticoagulant is
recommended for 3 weeks prior to ablation. For patients at low risk of stroke, the need for this is unknown.
–TEE or other methods to exclude intracardiac thrombus prior to ablation is recommended in patients with persistent AF or other high-risk
characteristics.
–If INR has been therapeutic every week for the 4 weeks preceding the ablation, the TEE could be avoided.
During Ablation
–Heparin administration should be initiated at the time of the exchange of short vascular sheaths for transseptal sheaths, and no later than immediately
after transseptal puncture is safely accomplished.
–Heparin should be administered as an initial bolus dose of 100–140 IU/kg followed by an infusion of 15–18 IU/kg/hour and/or by additional boluses.
For patients with an INR range of 2.0–3.5, the initial bolus dose should be reduced to 80 IU/kg.
–The ACT target should be 350–400 seconds based on limited data. The ACT target does not differ in patients with and without a therapeutic INR.
–Heparin infusion is discontinued in all patients after removal of catheters from the LA. Protamine infusion may be administered (dose 30–50 mg) or
ACT allowed to decrease below 250 seconds prior to sheath removal to minimize the potential for femoral hematoma formation.
–Ablation on therapeutic coumadin could be considered.
Postablation
–Oral anticoagulation should be started after ablation and continued for at least 3 months in all patients.
–Oral anticoagulation should be continued indefinitely in most patients who are at moderate or high risk of stroke (based on a risk stratification system
such as CHADS2 or CHA2DS2-VASc). This recommendation is based on a known risk of AF recurrence, and a lack of randomized, prospectively
obtained trial data indicating the safety of anticoagulation discontinuation.
Pericardial Effusion/Cardiac Tamponade
A risk of 1.3% for cardiac tamponade has been reported
in the last worldwide survey on AF ablation outcome.151
Clinical manifestations of acute tamponade include hy-
potension, tachycardia, paradoxical pulse, jugular venous
distension, and shock.
Monitoring with ICE or TEE and direct visualization of
the transseptal puncture may help minimize risk.190 Cautious
LA catheter manipulation and careful titration of RF power
delivery seems to reduce direct LA trauma and tissue boiling
with endocardial rupture.
Most large effusions can be drained with a percuta-
neous technique with documentation of the absence of
ongoing bleeding. Occasionally, open-heart surgery, includ-
ing cardio-pulmonary bypass may be required particularly
when ongoing bleeding after initial drainage is evident and
substantive.191
Recently, cases of delayed cardiac tamponade (i.e., oc-
curring after discharge from the EP lab or from hospital)
have been reported, sometimes preceded by evidence of
pericarditis.192
Thromboembolic Events
The prevalence of thromboembolism during or after AF
ablation has been reported to vary from 0% to 1.1% in differ-
ent studies.151,180,183,184,187 For the possible causes, preven-
tion and therapy of this complication see the previous section
on periprocedural and long-term anticoagulation.
PV Stenosis
With the evolution of PV isolation techniques and abla-
tion at the PV ostium or even more proximal at the antral
level, the incidence of severe PV stenosis has decreased to
0–0.5%.151,180,183,184,186,187 However, PV stenosis may be
underreported because most of the patients remain asymp-
tomatic and postablation imaging is no longer routine at most
centers. In the updated worldwide AF ablation registry, the
rate of PV stenosis requiring intervention was 0.29%.151
The clinical manifestation of PV stenosis may be quite
insidious. Many people are asymptomatic if only single
PV stenosis is present even when marked (>70%).193 The
most frequent symptoms of PV stenosis are cough, dysp-
nea, hemoptysis, or recurrent and drug-resistant pneumo-
nia.194-196 Symptoms may develop both early and/or late
after the procedure with most patients presenting within
2–6 months.194
To reduce the risk of PV stenosis when RF-ablation is per-
formed near the PV ostium, the anatomy should be clearly
defined using angiography of the PVs, ICE, or 3D mapping
systems with image integration of preprocedure acquired MR
or CT imaging. Avoidance of lesion placement within venous
structures is critical.194 Cryo-energy was promoted to elim-
inate the risk of PV stenosis.33-35 However, the first cases
of PV stenosis after cryo-balloon PV isolation have been
reported recently.197
Significant (>70%) PV stenosis in symptomatic patients
should be treated by angioplasty and/or stenting.198 Angio-
plasty is associated with high restenosis rate of 45%.198,199
PV stenting with bare metal stents with a size of ≥10
mm200,201 or drug-eluting stents202 seem to reduce the
restenosis rate. Because of the disappointing surgical results
for congenital stenosis, surgery should be considered the
treatment of last resort. Whether patients with 1 PV stenosis
and no or minimal clinical symptoms should be treated is not
yet known. Anticoagulation is typically maintained if severe
stenosis is present to prevent acute thrombosis.
Phrenic Nerve Injury
The estimated incidence of phrenic nerve injury is be-
tween 0.1% and 0.48%.203,204 The right phrenic nerve is
vulnerable to collateral injury during energy delivery at or
close to right superior PV and superior vena cava.205 The
left phrenic nerve is susceptible to damage when lesions are
applied in the vicinity of the LA appendage.206
Phrenic nerve injury appears to be clinically silent in many
patients (22–50%),203,204 with the majority of the remain-
ing patients presenting with mild symptoms such as dysp-
nea, cough, and weakness. However, some patients develop
more severe lung complications such as pneumonia, atelec-
tasis, pleural effusion, and respiratory failure. Surgical plica-
tion of the paralyzed right diaphragm may be required. The
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diagnosis of phrenic nerve injury can be confirmed by fluo-
roscopy demonstrating a positive “sniff test” and the presence
of unilateral diaphragmatic paralysis.
Despite the low prevalence and apparent benign course in
most patients, prevention of persistent phrenic nerve injury
is possible by identification of phrenic nerve location with
high-output pacing (≥30 mA, 2 ms).203,204,207,208 Such a ma-
neuver is recommended before energy delivery at or near the
anterior aspect of right superior PV, the superior vena cava,
and the LA appendage roof and, in the case of diaphrag-
matic contraction, ablation should be avoided. Other methods
have recently been reported to allow RF delivery in regions
where phrenic nerve injury would be expected. Applying an
intra-pericardial balloon209,210 and progressive infusion of
air and saline in the pericardial space211 to separate the
phrenic nerve from the epicardial surface has allowed suc-
cessful ablation without phrenic nerve injury. Another option,
with greater inherent risk, includes close monitoring of the
diaphragmatic excursion with immediate offset of ablation
upon its reduction or if hiccups develop.
Atrio-Esophageal Fistula
Atrio-esophageal fistula formation is a rare but nearly uni-
versally fatal complication of AF ablation. A nationwide sur-
vey reported an incidence of 6 cases in 20,425 LA procedures
(0.03%) with 5 deaths.212 The mean time to presentation of
this complication is 12.3 days213 but it has been described as
late as 41 days.214
Because of the high risk of death,212,213 atrio-esophageal
fistula, when occurs, requires rapid and accurate recognition
and diagnosis. Fever, malaise, leukocytosis, dysphagia, he-
matemesis, and neurological symptoms in patients with a
recent catheter ablation procedure should raise suspicion of
atrio-esophageal fistula. If a fistula is suspected, it is impor-
tant that endoscopy is avoided because insufflation of the
esophagus can cause massive air emboli through the fistula
leading to stroke and myocardial infarction.213,215-218 Cur-
rently, imaging techniques such as MR or CT are used to
diagnose an atrio-esophageal fistula. CT of the chest or head
revealing intravascular air should immediately suggest the
possible diagnosis.
Monitoring of esophageal location/temperature and low-
energy short-duration delivery on the posterior LA are all
means utilized to minimize risk of the atrio-esophageal fistula
during AF ablation.219 However, until now there are no data
that clearly favors an approach on another.
Although mortality of atrio-esophageal fistula is very
high, previously published reports documented survival
following rapid surgical correction or esophageal stent-
ing.220,221
Periesophageal Vagal Injury
An unusual extracardiac complication of AF ablation
characterized by abdominal bloating and discomfort occur-
ring within a few hours to 2 days after the procedure has been
described.222 The incidence of such adverse event was 1% in
a series of 367 patients.222 This rare complication is probably
due to LA RF energy delivery affecting the periesophageal
vagal plexus. Upper gastrointestinal investigation showed a
pyloric spasm, gastric hypomotility, and a markedly pro-
longed gastric emptying time. To avoid this complication,
the authors suggested using esophageal temperature moni-
toring and avoiding the ablation of LA endocardium directly
overlying the esophagus.
Vascular Complications
Vascular complications including femoral artero-venous
fistula, pseudo-aneurysm, and large hematomas are common
after AF ablation (0.2–2.5%).151,180-187 These complications
are due to the numerous vascular access sites required for the
procedure and high intensity anticoagulation during and fol-
lowing the procedure. The prevalence of pseudo-aneurysm
ranges from 0% to 1.0% and the prevalence of AV fistula from
0% to 0.97% in large series.151,180,182-185,187 Suggestions for
limiting vascular complications include use of smaller gauge
needles for venous access, avoid femoral arterial access, per-
form procedure on warfarin anticoagulation to avoid the need
for “bridging” anticoagulation, decreasing number of sheaths
in 1 vein, use of micropuncture kits, and use of ultrasound
guided access in obese patients.223,224
Treatment of pseudoaneurysm depends on the size and
complexity and can include surgical repair but most are
treated with ultrasound guided compression and thrombin
injection.225,226 Treatment of AV fistula is also dependent
on the size and complexity and includes simple observa-
tion, ultrasound guided compression, endovascular stent and
surgery, but most can be treated with simple observation.227
Acute Coronary Artery Injury
Linear lesions deployed in the mitral isthmus can create
coronary circumflex injury. Fortunately, the incidence of this
complication is very low (0.002% in a large clinical experi-
ence with 71% of the study group having RF energy delivered
in the CS).228
Assessing the location of the circumflex coronary vessel
and its proximity to the planned ablation sites although not
routinely performed should be considered with careful power
titration as appropriate.
Air Emboli
Air emboli may enter the arterial system during transsep-
tal puncture, sheath/catheter exchanges, aspiration, irriga-
tion, intravenous medication administration or continuous
infusion of sheaths.229-231
An air embolus often travels to the right coronary artery
and mimics typical clinical presentations of acute inferior
myocardial wall ischemia. Air emboli may also travel to
cerebral circulation and may lead to severe neurological man-
ifestations.
Air emboli are best prevented by proper attention to
catheter and sheath technique. Caution should be exercised
when exchanging the sheaths and catheters. Air filters can be
used to minimize the risk of a large air embolus. If sheaths
are continuously irrigated throughout the procedure, auto-
matic pumps capable of detecting air in the tubing should be
considered.
Air embolus to the coronary arteries often resolves within
several minutes without major complications and residual
myocardial injury. If the signs of an embolus persist, coronary
angiography and, if necessary, aspiration of air from within
the coronary artery should be considered. Treatment of large
cerebral air emboli with prompt hyperbaric oxygen may have
clinical value.232
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Catheter Entrapment in the Mitral Valve or PV
The original worldwide survey on AF ablation on 7,154
patients reported an incidence of 0.01% of valve damage due
to catheter entrapment in the mitral valve apparatus.233 The
CMC is at particular risk for entrapment within the mitral
apparatus.234
Several recommendations can be made to reduce the risk.
First, the CMC should be positioned in the posterior LA dur-
ing transseptal catheterization. Second, the catheter should be
torqued in a clockwise direction when leaving the transseptal
sheath. These first 2 tips have allowed for safe catheter ma-
nipulation and successful ablation even in the setting of prior
mitral surgery and prosthetic mitral valve.235,236 Third, it is
recommended to advance the catheter and/or the sheath over
the catheter when mitral valve entrapment is observed.237 Fi-
nally, early surgical extraction should be strongly considered
before forceful manual extraction.238
Rarely the CMC can get entrapped in the PV with the
potential risk of laceration and intrapulmonary bleeding.239
Organized Left ATs After AF Ablation
Organized left ATs are common after AF abla-
tion with a reported incidence of 1.2–40% (Table
11).72,76,96,115,116,240-255 The variability in the frequency of
occurrence and the mechanism of the tachycardia appears to
be clearly dependent on the type of ablation procedure used
and the extent of the underlying atrial disease.247,251,252,256,257
Centers utilizing circumferential PV ablation combined with
additional linear lesions in the LA, targeting of CFAEs and
other more extensive LA ablation report a higher prevalence
of macro-reentrant atypical flutters and an overall incidence
of organized left ATs that is more than 5–10 times that
observed with only PV isolation.72,76,96,115,116,240-252,256,257
This is especially true if no attempt is made to es-
tablish/confirm a line of bidirectional block or anchor
clusters of more extensive LA ablation to anatomic
obstacles.145,258,259
The macro-reentrant circuit of atypical flutter typically
moves around a large anatomic barrier such as the mitral an-
nulus or ipsilateral PVs and typically incorporates a zone of
slow conduction created by gaps in LA linear lesions.260,261
Occasionally circuits can occur around the fossa ovalis, from
the CS musculature and adjacent LA or involve smaller cir-
cuits around anatomic barriers related to prior surgical or
catheter-based lesions.262,263 Centers that utilize PV isolation
have predominantly localized reentrant left ATs originating
from reconnected PVs.244,246,253,257
Patients with organized left ATs are frequently very symp-
tomatic because they tend to demonstrate 2:1 AV conduction
and a faster ventricular rate than observed in response to AF.
Despite the general poor response to medical therapy and fre-
quent recurrence after cardioversion, attempts to temporize
are still recommended when the arrhythmia is observed early
postablation. This is especially true given the fact that up to
50% of these tachycardias appear to resolve spontaneously
during the “healing phase” postablation.116
Depending on the underlying mechanism, the ablation
strategy may require isolation of the reconnected PV segment
(for focal or local re-entrant tachycardias of PV origin) or
may involve targeting the zone of slow conduction or a well-
defined anatomic isthmus for macro-reentrant flutter.72,244,257
It is routine to re-isolate PVs even if the mechanism of the
LA flutter is macro-reentry to minimize the risk of manifest
AF and recurrent LA flutter if lines of block do not hold long
term. Overall, ablation is quite effective for these postablation
left ATs with reported long-term success in excess of 80%.72
Adverse Impact on Atrial Contractility
Reverse remodeling of the left cardiac chambers with
improvement in function has been reported after success-
ful RF catheter ablation of paroxysmal and persistent
AF.27,143,144,264-273 However, the consequences of RF abla-
tion on the LA contractility are still somewhat inconsistent
based on published reports.
A recent meta-analysis, including 17 studies and 869 pa-
tients, assessed the effects of AF catheter ablation on LA
size, volume, and function. Independent of the technique ap-
plied there was a significant decrease in LA diameters and
volumes during follow-up in patients without AF recurrence
but not in those with AF recurrence. LA ejection fraction
and LA active emptying fraction did not decrease in patients
without AF recurrence, whereas they decreased in those with
AF recurrence.272
It appears that the effects of RF ablation on LA function
are dependent on the extent of ablation and time they are as-
sessed. Extensive ablation during PV antral isolation causes
initial impairment in atrial function; however, the positive re-
modeling that occurs with rhythm restoration in patients with
a high burden of AF typically outweighs negative effects of
ablation.270,271
It is important to recognize that studies performed till
now have used different protocols to evaluate the LA size,
have included different patient populations, and incorporated
different ablation techniques. These limitations suggest that
more investigation and standardization is required in this
important area.
It is also noteworthy that, very recently, a new syndrome,
so-called “stiff LA syndrome,” has been described as possi-
ble complication of AF ablation.274 The syndrome, although
rare (incidence of 1.4%), is clinically significant and char-
acterized by dyspnea, congestive heart failure, LA diastolic
dysfunction, and new-onset pulmonary hypertension.274
Radiation Exposure During Catheter Ablation of AF
Catheter ablation of AF frequently requires a long fluo-
roscopy time. Although single ablation procedure brings a
very low cancer risk, repeated procedures are usually asso-
ciated with a measurable risk increase. Consequently, every
effort should be made to abate total radiation time during AF
ablation.275-279
Very low frame rate pulsed fluoroscopy systems have be-
come the norm to minimize radiation exposure during ab-
lation procedure. Limiting cine-angiography, avoidance of
magnification and changing the angulation of fluoroscopic
equipment are other helpful measures to reduce fluoroscopy
time. Electro-anatomic and remote navigation systems that
facilitate catheter placement and stability further help to re-
duce radiation exposure.280-282 Operator exposure can also
be reduced by use of appropriate lead shielding.283
Skin radiation “burns,” with proper operating equipment,
are currently extremely rare as a result of AF ablation.284,285
The key points regarding periprocedural and late compli-
cations are reported in Table 12.
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TABLE 11
Iatrogenic Postatrial Fribrillation Ablation LAT/FL: Literature Data
Number of LAT/FL Time to Mean Acute Chronic Mean
Author Patients (%) LAT/FL (mo) TCL (ms) Macroreentry Focus Success (%) Success (%) Follow-Up (mo)
Kanagaratnam et al.240 71 14 (20) NR NR 5/5† 0 100 100 NR
Villacastin et al.241 30 2 (6.6) 2 240 2 0 100 100 6.5
Oral et al.242 80 1 (1.2) NR NR 1 0 100 100 NR
Ernst et al.243 88 6 (7.0) NR NR 6 0 100 100 NR
Gerstenfeld et al.244 341 10 (3.4) 5.7 ± 2.8‡ 253 ± 33 1 8 100 100 6.7 ± 2.3
Mesas et al.115 276 13 (4.7) 2.6 ± 1.6‡ 275 ± 25 11 3 100 87 2.5 ± 1.2
Pappone et al.245 560 39 (7.0)§ 2.4/2.9 NR 31 8 100 100 6.3/8.2
Jaı̈s et al.76 100 12 (12) NR NR 9 3 100 87¶ 12
Oral et al.96 100 21 (21) NR NR NR NR NR NR NR
Ouyang et al.246 100 21 (21) 0.21 206 17 2 100 100 5.8 ± 1.8
Cummings et al.247 737 23 (3.1) NR NR 23 0 100 61 16.5 ± 2.9
Hocini et al.248 20 4 (20) 4 ± 1‡ NR 4 0 100 100 NR
Chugh et al.116 349 85 (24) 1.5 ± 2.0 238 ± 35 28/28† 0 88 82 7.5 ± 4
Shah et al.249 207 16 (8) 2.3 ± 2.0 271 ± 45 15/15† 0 93 87 21 ± 11
Daoud et al.251 112 28 (25) 1.0 ± 0.5 NR 9/9† 0 94 NR NR
Deisenhofer et al.250 67 21 (31) 3.2 ± 3.1 264 ± 41 16/16† 0 89 38 10.4 ± 6.7
Chae et al.252 800 78 (10) NR 256 ± 49 137/155 18/155 86 77 13 ± 10
Sawhnet et al.253 66 8 (12) 9.8 ± 4.9†‡ NR 9/9 0 100 83 NR
Rostock et al.254 320 128 (40) NR†‡ 270 ± 40 44/61† 17/61† 93 82 21 ± 4
Chang et al.255 452 87 (19) NR†‡ NR 84/120 36/120 90 97 21 ± 16
Adapted from Raviele A, Themistoclakis S, Rossillo A, Bonso A. Iatrogenic postatrial fibrillation ablation left atrial tachycardia/flutter: How to prevent and
treat it? J Cardiovasc Electrophysiol 2005;16:298-301.72
†Only a limited number of the total population of patients with LAT/FL underwent repeat ablation procedure.
‡Time to LAT/FL ablation.
§28 (10%) in the 280 patients who were randomized to circumferential ablation alone, and 11 (3.9%) in the 280 patients who were randomized to
circumferential plus linear lesions ablation.
¶Regards both AF and LAT/FL.
TABLE 12
Key Points Regarding Periprocedural and Late Complications
–Recognition of common and unique complications related to AF ablation
can minimize the risk and optimize the outcome of ablation procedure.
–In order to reduce the risk, operators must be familiar with risk factors,
clinical signs, and symptoms of early as well as delayed occurring
complications.
–The rate of major complications of AF ablation ranges from 0.8% to 5.2%
according to the ablation strategy used, lesion extension, patient
characteristics, and center experience.
–Death occurs, as complication of AF, in 1 of 1,000 patients.
–The most common complications of AF ablation are vascular lesions,
cardiac tamponade, and thromboembolic events. Other complications
(e.g., atrio-esophageal fistula), although rare, may be very serious and
life-threatening.
Short- and Long-Term Efficacy of Catheter Ablation
for AF
Since the Venice Chart International Consensus Docu-
ment in 2007,1 more data have become available describ-
ing the acute, mid/long-term and very long-term efficacy
of catheter ablation for AF. In order to define the success
rates of any given procedure, there must be a consistent ap-
proach to the technique, a well-accepted method of follow-
up, and a strict definition of success. Fortunately, over the
last few years, a fairly good agreement has been reached
on all the above-mentioned criteria. For most studies in pa-
tients with paroxysmal AF, PV isolation is considered a suffi-
cient endpoint for ablation. Additional linear ablation and/or
targeting of CFAEs has largely been reserved for patients
with more persistent AF. Most studies have conformed to the
HRS/EHRA/ECAS Expert Consensus Statement recommen-
dations that follow-up postablation should be a minimum of
12 months with ECGs and 24-hour Holter monitors at least
every 3 months.101 Finally, the definition of success has be-
come more standardized. For the most part, early recurrences
occurring within the first 3 months after the procedure are
discounted as being due to inflammatory changes and/or in-
complete healing of the lesion sets, part of the so-called
“blanking period.” Recurrences after 3 months have been
defined as episodes of AF lasting >30 seconds for reporting
purposes, although the relevance of such short episodes of
AF is not known.101
Acute Efficacy of AF Ablation
Acute recurrences of AF are not uncommon within the first
2–3 months postablation. Studies suggest that the incidence
of early AF recurrence ranges from 35% to 50%.286-288 These
studies also show that most patients who go on to have late
recurrence have usually had recurrence within the first 3
months. However, as many as 50% of patients who have
early recurrences will not continue to have AF in the longer
term.286,287 While most studies use a 3-month blanking, as
recommended by the HRS/EHRA/ECAS Expert Consensus
Statement, other data have suggested that 2 months may
be long enough.289 Many studies have also used temporary
AADs therapy during the blanking period to prevent early
recurrences, supported by the 5A trial.139
Mid- to Long-Term Efficacy of AF Ablation
In patients with paroxysmal AF and minimal structural
heart disease, consistent success rates for catheter ablation
can be achieved. In these patients, the success rate at 1 year
off AADs is 60–75% after single procedure and 65–90% after
908 Journal of Cardiovascular Electrophysiology Vol. 23, No. 8, August 2012
multiple procedures.151,290 A number of recent systematic re-
views have been published comparing the efficacy of catheter
ablation of AF to AADs therapy.291-294 The technique used in
these studies was a PV isolation technique with little to no ad-
juvant ablation performed. The results of all of these reviews
showed superiority of RF ablation over AADs therapy with
a success rate of 75.7–77%.291,294 A single repeat ablation
procedure was required in 10–25% of patients, increasing
the chance of off-drug success by an additional 5–15%.295
The results of single prospective randomized trials published
after the first Venice Chart International Consensus Docu-
ment were similar.296-302 In the 4A study, Jais et al. showed
an 89% success rate at 1 year with catheter ablation (mean
1.8 ± 0.8 procedures) compared to 23% success for AADs (P
< 0.001; n = 112).300 In a large, multicenter, randomized trial
with RF ablation and an intensive postablation monitoring
regimen, Wilber et al. reported a 66% single-procedure suc-
cess rate at 1 year compared with only 16% with AADs (P <
0.001; n = 167).301 Finally, in the STOP-AF trial, which uti-
lized cryo-ablation balloon technology for PV isolation, 245
patients were enrolled and the ablation group had a 69.9%
success rate at 1 year (after 1 or more procedures) compared
with only 7.3% success rate with AADs (P < 0.001).302
Very Long-Term Efficacy of AF Ablation
Data on very long-term outcomes from AF ablation, be-
yond 1 year, are more limited and largely restricted to single-
center experiences (Table 13).146,147,167-177 A few studies
have shown that outcome of AF ablation beyond 1 year is
preserved. Weerasooriya et al. described 1 high-volume cen-
ter’s experience over 5 years of follow-up in both paroxysmal
(63%) and persistent AF patients, showing that the majority
of recurrences occur within 6 months of the ablation pro-
cedure. Success rates at 1, 2, and 5 years were 87%, 81%,
and 63%, respectively, with a median of 2 procedures per pa-
tient.176 Other authors reported similar results.167,169,172,177
Risk factors for very late recurrence appear to be nonparox-
ysmal AF, valvular heart disease, cardiomyopathy, and ad-
vanced age.176 Other studies, however, have published less
optimistic results.146,147,168 Wokhlu et al. reported that the
risk of recurrence increased in absolute terms by 12% in
paroxysmal patients and 20% in persistent patients from year
1 to year 2.5.147 Bertaglia et al. published that the actuarial
atrial arrhythmia recurrence rate was 13.0% at 2 years, 21.8%
at 3 years, 35.0% at 4 years, 46.8% at 5 years, and 54.6% at
6 years.146 However, in both of these studies, the initial suc-
cess rates were substantially lower than those reported in the
previous section. Perhaps a difference in ablation technique
is resulting in a higher late recurrence rate. Furthermore,
although recurrences may be common, performing an addi-
tional procedure may still provide very long-term success, as
described by Sawhney et al.170
Efficacy in Nonparoxysmal AF
In general, the success rate of AF ablation is lower in pa-
tients with persistent or long-lasting persistent AF compared
to paroxysmal AF.303 Many studies show success rates of
40–70% in nonparoxysmal AF and many have suggested the
need for supplemental substrate modification in addition to
PV isolation.35 In a recently published meta-analysis of abla-
tion in persistent AF, the pooled, single procedure, drug-free
success rate was only 44% in 211 patients who underwent
wide antral PV isolation alone.303 With repeat procedures
TABLE 13




Patients Follow-Up Procedure Procedures
Authors (No.) (Months) (%) (%)
Shah et al.167 264† 28 ± 12 8.7% 3%
Katritsis et al.168 35 42 ± 6 79% 34%
Bhargava et al.169 1,404 57 ± 17 27% 10%
Sawhney et al.170 71 63 ± 5 44% 16%
Bertaglia et al.146 177† 49 ± 13 42%
Wokhlu et al.147 774 36 ± 23 36%
Miyazaki et al.172 574 27 ± 14 34% 16%
Tzou et al.173 123† 60 29%
Ouyang et al.174 161 54 53% 20%
Medi et al.175 100 39 ± 10 51% 18%
Weerasooriya et al.176 100 60 71% 37%
Pappone et al.177 99 48 27%
†Patients free of arrhythmic recurrences at 1-year follow-up.
TABLE 14
Key Points Regarding the Short and Long-Term Efficacy of Catheter
Ablation for AF
–Early recurrences of AF are not uncommon during the first 2–3 months
postablation (35–50%). These arrhythmias tend to disappear after the
initial period in 50% of the cases and not necessarily express procedural
failure.
–AF ablation is an effective therapy over the mid/long term. In the first
year following ablation, the success rate after multiple procedures is
65–90% for paroxysmal AF and 40–70% for nonparoxysmal AF.
–Outcome for AF ablation seems to be preserved also beyond 1 year with
only few very late recurrences; additional data, however, are required to
this regard to confirm the robustness of the therapy.
–Prospective randomized trials conducted in a limited number of patients
with paroxysmal AF have systematically shown that AF ablation is
superior to AADs therapy in controlling AF; however, whether this
translates into reduced morbidity and mortality remains to be assessed.
–Clinical factors predictive of procedural failure include nonparoxysmal
AF, advanced age, hypertension, diabetes, sleep apnea syndrome, LA
enlargement, LA scarring, and structural heart disease, such as
cardiomyopathy or valvular heart disease.
and concomitant AADs therapy, the success rates increase
to 59% and 77%, respectively. Addition of adjuvant ablation
may further improve outcome. The drug-free, 1 procedure
success rate of PV isolation + linear ablation ranges from
48% to 57%,303 which is better than that of PV isolation
alone. Similarly, the success rate of PV isolation + CFAEs is
higher than that of PV isolation alone: 51% with 1 procedure
and 77% with 2 procedures.63,66,304
Mechanisms of AF Ablation Failure
Studies have shown that the mechanism for long-term
recurrence is linked to the recovery of electrical conduc-
tion between the PVs and the LA both in patients with
paroxysmal and nonparoxysmal AF.305 Recurrence, partic-
ularly atrial flutters, may also be related to incomplete scars
created by the initial ablation.253 Re-isolation of the PVs
is quite often effective in treating recurrent AF or atrial
flutters.247 However, performance of additional ablation may
be required, such as linear ablation or ablation of CFAEs,
particularly in nonparoxysmal AF.306 The mechanism of very
late recurrences beyond 1 year may also involve development
Raviele et al. Venice Chart on AF Ablation 2011 Update 909
Figure 3. Indications to catheter abla-
tion of AF. (A) Patients with paroxysmal
AF. (B) Patients with persistent AF and
long-lasting persistent AF.
of non-PV triggers, either outside of the PV antra in the LA,
or even within the CS and right atrium.172,307
A number of clinical factors predict late failure of AF
ablation. In particular, LA scarring may be the strongest pre-
dictor of procedural failure.124,308 Other risk factors include
significant LA enlargement, advanced age, nonparoxysmal
AF, and structural heart disease, such as cardiomyopathy
or valvular heart disease.147,176 Diabetes, hypertension, and
sleep apnea syndrome have also been reported as risk factors
for late recurrence.146,287,309
The key points regarding the short- and long-term efficacy
of catheter ablation for AF are reported in Table 14.
Indications to Catheter Ablation of AF and
Cost-Effectiveness
Indications to Catheter Ablation of AF
Several studies from high-volume centers have demon-
strated the efficacy of catheter ablation for AF, mainly in pa-
tients with paroxysmal AF.113,169,170,174,296-301,310,311 There-
fore, catheter ablation of paroxysmal AF in symptomatic
patients is an established indication in experienced centers
after failure of AADs therapy (second-line therapy) (Fig.
3A) and LA size and left ventricular function are important
to define the class of recommendation according to latest US
guidelines for the management of patients with AF.312,313
Class I, level of evidence A, is now recommended for pa-
tients with normal or mildly dilated LA and normal or mildly
reduced left ventricular function without severe pulmonary
disease.313 Class IIa, level of evidence A, is recommended for
patients with dilated LA or reduced left ventricular function
and class IIb is recommended for patients with significant
LA enlargement or significant LV dysfunction.313 Ablation
of persistent AF is feasible as second-line therapy after fail-
ure of medical treatment (Class IIa, level of evidence A)
(Fig. 2B),313 but there is no real consensus since the proce-
dure is more complex with a lower success rate. For these
reasons, catheter ablation of persistent AF requires a more ac-
curate selection of patients and, particularly among patients
with long-standing persistent AF, multiple interventions are
frequently necessary to increase the success rate.169 Thus,
more data are needed to determine the most suitable candi-
dates with long-standing AF for ablation (Fig. 3B). A new
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Class I first-line indication for catheter ablation of AF is
proposed for selected patients with very symptomatic parox-
ysmal AF (Fig. 3A).296 This approach will require an accu-
rate selection of candidates that includes patient preference
for nonpharmacologic therapy, the absence (lone AF) or the
presence of “minimal” structural heart disease, relatively fre-
quent AF, e.g., >2 episodes/month, and with operators that
are very experienced. For these highly selected patients the
ablative procedure may be performed at an earlier stage of
the disease296,311 to avoid or limit arrhythmia progression to
more persistent forms,311 which is associated with lower suc-
cess rate and with an increased need for repeat procedures.
Cost-Effectiveness
Whereas several studies have reported the costs of AF ab-
lation, limited information is available on cost-effectiveness
of the procedure.314-320 The issue is further complicated by
the fact that cost-effectiveness of AF ablation is influenced
by several factors, the most relevant of whom being the
type of AF, the clinical characteristics of patient popula-
tion, the duration of the follow-up, the intensity of ECG
monitoring, the success and complication rates of the pro-
cedure, the experience of the ablation centers, the costs of
ablation tools and drug therapy and the differences in re-
source utilization.321,322 In general, cost-effectiveness is bet-
ter in patients with paroxysmal AF, with no or minimal heart
disease, highly symptomatic with higher CHADS2 score,
treated in high-volume centers and followed for a sufficiently
long period of time.321,322 Under these conditions, the initial
higher costs of ablation procedure are usually offset by the
subsequent higher costs of AADs within a period of time
ranging from 2 to 5 years or more.314,318 In a recent study,
the incremental cost-effectiveness ratio for AF ablation ver-
sus AADS was 51.431 $ per quality-adjusted life-year.319
This suggests that AF ablation is a reasonably cost-effective
therapy.
The key points regarding indications and cost-
effectiveness of catheter ablation of AF are reported in
Table 15.
Clinical Trials on AF/Future Perspectives
Available randomized studies of AF comparing catheter
ablation and AADs have essentially focused on recurrences
of AF, either clinically or electrocardiographically, and only
to a lesser extent on measurements of quality of life.296-302
Moreover, in these studies, no attempts were made to evaluate
the effect on hospitalization, long-term survival, and throm-
boembolic complications, as the number of patients included
was too small and the follow-up too short. The scientific ev-
idence is also insufficient for drawing definitive conclusions
about the cost-effectiveness of the AF ablation therapy, since
its long-term effects are still uncertain. Therefore, further
large randomized trials are needed to better clarify the real
impact of AF ablation on these clinically relevant issues. Sev-
eral ongoing trials have been planned to this regard.323 Some
(e.g., CABANA, EAST, and CASTLE-AF) are focused on
mortality, hospitalization and stroke, others (e.g., RAAFT-2
and MANTRA-PAF) will test the effectiveness of catheter
ablation early in the treatment of AF, and some more will
assess the role of AF ablation in patients with heart failure
(e.g., AATAC-HF, AMICA and ARC-HF) or with persistent
TABLE 15
Key Points Regarding Indications and Cost-Effectiveness of Catheter
Ablation of AF
Paroxysmal AF
–As second-line therapy, after failure of AADs, catheter ablation is an
established indication in symptomatic patients. The class of
recommendation depends on LA size and left ventricular function.
–As first-line therapy, catheter ablation may be indicated in a very
selected group of highly symptomatic patients with no or minimal heart
disease and relatively frequent episodes of AF.
Persistent/Long-Lasting Persistent AF
–As second-line therapy, after failure of AADs, catheter ablation is
feasible in symptomatic patients, but the selection has to be accurate
because the procedure is more complex and associated with lower success
rate and higher need for repeat interventions.
Cost-Effectiveness
–Catheter ablation of AF is a reasonably cost-effective therapy provided
that the selection of patients is appropriate.
TABLE 16
Key Points Regarding Clinical Trials on AF/Future Perspectives
–Multiple randomized trials have demonstrated a superiority of AF
ablation over AADs therapy in patients with drug-refractory symptomatic
paroxysmal AF. Catheter ablation significantly reduces AF recurrences
and hospitalizations, and improves quality of life.
–The effects of catheter ablation on hard endpoints such as mortality or
thromboembolic events remain to be established.
–Ongoing trials are evaluating effectiveness of catheter ablation in broader
patient populations, such as patients with nonparoxysmal AF and left
ventricular dysfunction, as well as the effects of ablation on hard
endpoints such as mortality.
and long-standing persistent AF (e.g., SARA).323-326 The re-
sults of these trials will further improve our understanding of
the clinical value of AF ablation.
The key points regarding clinical trials on AF/future per-
spectives are reported in Table 16.
Surgical Approach/Ablation of AF
Historical Aspects and Surgical Ablation Technologies
The surgical ablation era for the treatment of AF began
in the early 1980s. In 1987, the Cox-Maze (C-M) procedure
was introduced and then progressively modified over time.327
The last version, the C-M III procedure, proved to be highly
effective in eliminating AF with 97% of the patients free
from symptomatic AF at a mean late follow-up of 5.4 ± 2.9
years.328 However, it was technically difficult, highly inva-
sive, and associated with significant risks. With the intro-
duction of ablation devices in the last decades, only a small
number of cardiac surgeons still perform the cut-and-sew op-
eration today. Ablation devices have transformed the field of
AF surgery by decreasing procedural difficulty and operative
time, thus allowing for an application to a broader patient
population and for the development of minimally invasive
techniques.329 Many devices using different energy sources
have been proposed and employed for surgical treatment of
AF. They include RF (unipolar and bipolar), cryo-ablation
(nitrous oxide and argon-based technology), and high inten-
sity frequency ultrasound devices. Each ablation technology
has its own advantages and disadvantages. It is imperative for
surgeons to develop a complete understanding of the effects
of each specific ablation technology on atrial hemodynamic,
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function, and electrophysiology. This will allow for more
appropriate use of devices in the operating room.
Surgical Techniques and Outcome
There are a myriad of different surgical ablation proce-
dures that are presently performed. They can be grouped into
4 broad categories: the C-M procedure, PV isolation alone,
PV isolation with left atrial lesion sets, and hybrid approach.
C-M procedure
The original cut-and-sew C-M III procedure is only rarely
performed today. At most centers, the surgical incisions have
been replaced with lines of ablation using a variety of en-
ergy sources. The most widely adopted variation has been
the C-M IV procedure, which utilizes bipolar RF energy to
replace most of the surgical incisions.330 This RF ablation-
assisted procedure incorporates most of the lesions of the
C-M III and is performed on cardiopulmonary bypass. The
operation can be done either through a median sternotomy
or a less-invasive right mini-thoracotomy.331 The PVs are
isolated with the bipolar clamps on the beating heart. It is
imperative to document entrance and/or exit block at the
time of surgery. In a large C-M IV series, the freedom from
AF was 89% and the freedom from AF off AADs was 78%
at 1 year, in the entire population of patients.332 In patients
undergoing a stand-alone C-M IV procedure for lone AF, the
results were even better with a freedom from AF of 90% and
freedom from AF off AADs of 84% at 2 years with no in-
traoperative mortality and no postoperative strokes.333 There
was no difference in success rates for patients with parox-
ysmal AF compared to those with persistent or long-lasting
persistent AF. Similar results have been obtained using cryo-
ablation or high intensity frequency ultrasound.
PV isolation alone
The PVs have been isolated either separately or as a large
box lesion incorporating the posterior LA. This procedure
may be performed through thoroscopy with a minimally in-
vasive surgical approach334 and may be associated with GP
ablation. In a recent study using this technique, the success
rate at 1 year was 65% with a low incidence of postopera-
tive complications.335 However, a number of studies support
the contention that PV isolation alone or associated to au-
tonomic denervation335,336 is inadequate for persistent and
long-lasting persistent AF due to the substrate changes in-
duced by electrical remodeling.
Expanded lesion sets
When connection lines to the mitral annulus are added, the
success rates are more satisfactory and comparable to those
of the cut and sew maze. Jeanmart and colleagues reported
an AF-free rate of 69.7% with an endocardial box lesion
plus a connecting line to the mitral annulus.337 However,
incorporation of the mitral valve isthmus can be challenging.
To overcome this problem and to replicate the LA lesions
of the C-M III, the Dallas lesion set was developed.338 With
this approach the connection to the mitral valve is made to
the anterior annulus at the left fibrous trigone.339 The other
lesions include a line from the right superior PV to the left
superior PV and a line from the left superior PV to the base
of the amputated LA appendage.340 In a multicenter registry,
including 124 patients treated with the Dallas lesion set, a
high success rate was measured: 63% in a group that had
previously undergone catheter ablation (n = 21) and 86% in
patients who had not been ablated before (unpublished data
provided by Edgerton JR).
Hybrid approach
Further frontiers include the use of hybrid approach, com-
bining the strengths of epicardial and endocardial ablation.341
Lesions are more likely to be transmural when burning in-
side and outside simultaneously. The potential for improved
outcomes through hybrid ablation also derives from com-
bining expertise levels. The demonstration of the efficacy of
this approach awaits the completion of currently underway
trials.
Indications
The current indications for surgical ablation as defined
in the HRS/EHRA/ECAS expert consensus statement101 on
AF ablation include: (1) all symptomatic patients with doc-
umented AF undergoing other cardiac surgical procedures;
and (2) selected asymptomatic patients with AF undergoing
cardiac surgery in which the ablation can be performed with
minimal risk in experienced centers. Moreover, surgical ab-
lation is indicated, as stand-alone procedure, in symptomatic
patients who either prefer a surgical approach, have failed 1
or more attempts at catheter ablation or are not candidates
for catheter ablation (Fig. 4). However, there are other rel-
ative indications for surgery, in particular for a stand-alone
procedure, that were not included in the HRS/EHRA/ECAS
expert consensus statement that should be taken into consid-
eration as first-line therapy in lieu of less invasive catheter
ablation. The following are examples: (1) AF patients who
develop a contraindication to long-term anticoagulation and
have a high risk for stroke (CHADS2 score ≥ 2) are excellent
candidates for surgery. The C-M procedure both eliminates
AF in most of these patients, and also amputates the LA
appendage. The stroke rate following the procedure off anti-
coagulation has been remarkably low, even in patients with
high CHADS2 scores;342 (2) surgical treatment for AF also
should be considered in patients with long-lasting AF who
have suffered a cerebrovascular accident despite adequate
anticoagulation. These patients are at high risk for repeat
neurological events. In a series of over 200 patients with a
stand-alone C-M procedure there was only 1 late stroke, and
over 80% of patients were off anticoagulation at last follow-
up;343,344 (3) finally, symptomatic AF patients with a clot in
the LA appendage who have failed medical therapy are not
candidates for catheter ablation and should be referred for
surgical ablation.
The key points regarding surgical approach/ablation are
reported in Table 17.
Hospital Equipment and Facilities, Personnel, Training
Requirements, and Competences
Hospital Equipment, Facilities, and Technological
Requirements
Centers involved in AF ablation procedures should be
equipped with state-of-the-art equipment. These should in-
clude the following:
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Figure 4. Indications to surgical ablation of AF. (A) Patients with paroxysmal AF. (B) Patients with persistent AF. (C) Patients with long-lasting AF.
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TABLE 17
Key Points Regarding Surgical Approach/Ablation of AF
–Surgical techniques for AF include Cox-Maze procedure, PV isolation
alone, PV isolation with LA lesion sets, and hybrid approach.
–The original “cut and sew” Cox-Maze procedure is only performed rarely
today. At most centers the surgical incisions have been replaced with lines
of AF ablation using a variety of energy sources (especially bipolar RF).
–The surgical procedures can be done either through sternotomy or
through thoracoscopy with a minimally invasive surgical approach.
–Success rates of surgical AF ablation vary between 65% and 90% during
follow-up. This great range can be attributed to many factors including
type of AF, patient characteristics, the use of different ablation devices
and energy sources, differing lesion sets, and surgeon experience.
–Surgical AF ablation is indicated in all symptomatic patients as well as in
selected asymptomatic patients with documented AF who undergo other
cardiac surgical procedures.
–Surgical AF ablation is also indicated, as stand-alone procedure, in
symptomatic patients with AF who either prefer a surgical approach, have
failed 1 or more attempts at or are not candidates to catheter ablation.
- Sedation, anesthesia and resuscitation equipment, includ-
ing pericardiocentesis materials, biphasic defibrillator, and
a mechanical ventilator.
- Up-to-date ECG, blood pressure, oxygen saturation, and
ACT monitoring equipment.
- Modern catheterization laboratories, including X-ray sys-
tems allowing dose-reduction and image optimization and
staff protection.
- A multichannel recording system (at least a 16-channel
recording system) and a multi-programmable stimulator.
- 3D electro-anatomical mapping: at least 1 system.
- RF power generators and/or cryoablation console.
- Cardiac imaging techniques, including at least transtho-
racic echocardiography and TEE and preferably also a
multislice-CT scanner or MR scanner.
- Intracardiac echocardiography (recommended but not
mandatory).
Other equipments, such as magnetic and robotic naviga-
tion systems and single-shot device systems, are promising
but their impact and superiority compared to the conventional
approach of AF ablation is unclear and remains speculative.
Training and Knowledge
Indications and patient selection
The physician (i.e., electrophysiologist) should be compe-
tent in counseling patients and evaluating the potential risks
and benefits of catheter ablation and should be able to direct
current recommendations to the specific needs of individual
patients.
Anatomical knowledge
The detailed knowledge of cardiac anatomy with specific
attention to LA and its adjacent structures is highly required
for performing the technical aspects of transseptal puncture,
cannulation of the LA and navigation and to avoid or reduce
the risk of procedure-related complications.
Interpretation of electrograms/knowledge in basic EP
studies
Every electrophysiologist performing catheter ablation of
AF must have achieved a proficiency in the ECG and in-
tracavitary electrograms interpretation. Recognition of PV
TABLE 18
Basic Technical Skills to be Proficient for an Atrial Fibrillation Procedure
–Vascular access and cannulation.
–Fluoroscopy system use and familiarity with fluoroscopic projections and
landmarks.
–Catheter manipulation and positioning.
–Set up and understanding of the electrophysiology system, including the
intracardiac recording system, the electrical stimulator, and the 3D
electro-anatomical system.
–Knowledge on materials and systems to manage complications
(defibrillator, pericardiocentesis kit, etc.)
potentials both at baseline and during CS pacing and when
PV electrical disconnection is achieved remains the corner-
stone of the ablation procedure. Correct identification and
interpretation of CFAEs is also important, because these po-
tentials may be a target for ablation in patients with persistent
and long-lasting persistent AF.
Knowledge of 3D mapping systems
An electrophysiologist who performs AF ablation proce-
dures must be familiar with the handling and interpretation, as
well as with the limitations of different 3D mapping systems.
Therefore trainees should be able to perform and interpret
the different types of electrophysiological analysis like acti-
vation mapping for the treatment of left-atrial macroreentrant
tachycardia, voltage mapping for substrate guided ablation
approaches and purely anatomical maps for conventional AF
ablation procedures.
Technical competence
Technical competence and skills in catheter, sheath and
guide wire manipulation are required.
Basic technical skills
Basic technical skills to be proficient for an atrial fibrilla-
tion procedure are listed in Table 18.
Transseptal puncture
A good knowledge of transseptal puncture techniques is
mandatory for all electrophysiologists involved in PV isola-
tion and other left-sided procedures.
Competence in performing basic EP studies and ablation
procedures
The European Heart Rhythm Association (EHRA)
presently recommends receiving formal training for at least
1 year in conventional electrophysiology procedures and sim-
pler ablations before being involved in AF ablation proce-
dures.345 Following this first year, the trainee should receive
formal training for at least another year in more complex
procedures, 1 of them being AF ablation. According to this
scientific organization the trainee should be directly involved
in a minimum number of 150 ablation procedures (35 to
be performed as the primary operator) and 10 transseptal
catheterizations (5 to be performed as the primary operator)
at the end of this 2-year period.345 The American Accred-
itation Council of Graduate Medical Education (ACGME)
recommends involvement in a minimum of 75 catheter ab-
lation procedures.346 However, these requirements are the
basis to be trained in ablation procedures in general and
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TABLE 19
Key Points Regarding Hospital Equipment and Facilities, Personnel,
Training Requirements and Competences
–Centers involved in AF ablation procedures should be equipped with
state-of-the-art equipment.
–The physicians should be competent in counseling patients and evaluating
the potential risks and benefits of catheter ablation on individual basis.
–Every electrophysiologist performing AF catheter ablation should have a
detailed anatomical knowledge of LA and its adjacent structures, must
have achieved a proficiency in the ECG and intracavitary electrograms
interpretation, and must be familiar with the handling and interpretation
of different 3D mapping systems.
–Moreover, technical competence and skills in catheter, sheath, and guide
wire are required.
–Although no scientific organization has established precise criteria,
participation in at least 30–50 mentored AF ablations and 10 transseptal
punctures is considered the minimum requirement to be considered
trained for AF ablation.
possibly more practical experience, especially in transseptal
catheterization, should be required to be fully competent to
perform AF ablation procedures as independent operator and
to manage potential complications, such as macroreentrant
left AT.101 To date, no scientific organization has established
a minimum number of AF procedures to be performed as pri-
mary operator in order to be considered fully trained for this
task. The American College of Cardiology and the American
Heart Association recommend participation in 30 to 50 men-
tored AF ablations.347 The former committee also recom-
mends involvement in 10 transseptal punctures.347 Anyhow,
some reports suggested that results improved in centers with
experience in more than 100 AF ablations.233
Management of Complications
Trainees must be familiar with risk factors, clinical signs,
and symptoms of potential early as well as delayed oc-
curring complications. Backup of an experienced physician
with skills in emergency needle pericardiocentesis is nec-
essary and training in pericardiocentesis definitely neces-
sary. Awareness of risks of conscious sedation (including
hypoventilation, aspiration, and respiratory arrest) as well as
management of those should be trained.
Follow-Up
Trainees must be familiar with the principles of adequate
rhythm monitoring following AF catheter ablation with clin-
ical trials necessitating more intense AF monitoring than in
clinical practice.101,348 The trainee must be familiar with indi-
cations and contraindications for cardioversion, concomitant
AADs use and timing of repeat ablation. Furthermore the use
of anticoagulation regimes must be set in the right context
with adequate risk-benefit evaluation of thromboembolic and
bleeding risks.
The key points regarding hospital equipment and facili-
ties, personnel, training requirements and competences are
reported in Table 19.
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